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ABSTRACT 
Both clinical and experimental evidence suggest that diabetes 
mellitus impairs cardiac performance to a greater extent in the 
presence of hypertension than it does in the absence of hypertension. 
There is also indirect evidence to suggest that a low thyroid state, 
which often coincides with experimental and clinical diabetes, may 
contribute to this impairment. The following study was designed to 
characterize selected cardiovascular sequelae of diabetes in the 
hypertensive rat, and to determine whether involvement of attendant 
hypothyroidism is functionally significant. The hypotheses of this 
study can be summarized as follows: 1) The marked depression in 
cardiac performance caused by diabetes in hypertensive rats is 
associated with impairments in sarcoplasmic reticular (SR) calcium 
uptake and with prolongations in the duration of ventricular muscle 
action potentials; and 2) Demonstrated disturbances in cardiac 
performance, SR calcium uptake, and action potential duration caused 
by diabetes could then be altered by either thyroid hormone or 
insulin treatment in vivo. To test these hypotheses, spontaneously 
hypertensive rats (SHR) were made diabetic with a single injection of 
streptozotocin (STZ; 45 mg/kg). Subgroups of diabetic animals were 
treated with either thyroid hormone (T 3; 8-10 µg/kg/day) or insulin 
(10-20 U/kg/day). After 8 weeks of untreated and treated diabetes, 
the following measurements were taken: 1) Indices of performance 
(contraction and relaxation) of perfused, working hearts ex vivo; 2) 
Rate and extent of calcium uptake by microsomal preparations of 
ventricular homogenates in vitro; and 3) Action potential profiles 
of papillary muscle in vitro. Control groups for various studies 
included nonhypertensive Wistar Kyoto (WI<Y) rats, and renovascular 
hypertensive (RVH) rats, to rule out strain-dependent effects in the 
SHR model, food-restricted nondiabetic rats to control primarily for 
reductions in heart size, and rats pretreated with 3-0-methylglucose 
to protect against the diabetogenic effects of STZ (as a control for 
nonselective STZ-induced cardiotoxicity). The results showed, first, 
that indices of left ventricular (LV) performance ex vivo (e.g., LV 
pressure generation and rates of contraction and relaxation) of SHR, 
but not WI<Y rats, were depressed by diabetes. Diabetes-induced LV 
mechanical deficits of SHR were ameliorated by either insulin or T3 
treatment. The adverse effects of diabetes on mechanical function of 
SHR hearts were independent of coronary macrolesions, as evidenced by 
normal coronary flow rates, myocardial oxygen consumption and 
coronary vascular resistance in the diabetic SHR group. These data 
provide additional evidence that a "diabetic cardiomyopathy" at least 
partially contributes to depressed function in the SHR and that 
thyroid hormone treatment can prevent at least a portion of the 
mechanical deficits. Second, the results showed that diabetes 
impaired LV relaxation and depressed rates of SR calcium uptake in 
the SHR left ventricle without affecting either measurement in the 
WKY group. Thyroid hormone treatment completely prevented these 
mechanical and biochemical changes in the diabetic SHR heart. The 
third component of the results indicated that diabetes prolonged the 
ventricular action potential to the same extent in the SHR as it did 
in the WKY. Either insulin or T3 treatment of diabetic SHR 
completely prevented the prolongation of the action potential. As it 
did in the SHR strain, diabetes also caused a marked depression in 
the performance in hearts of RVH rats. Similarly, T3 treatment of 
diabetic RVH, like T3 treatment of diabetic SHR, prevented the 
impairment of cardiac performance. Collectively, these results 
suggest that left ventricular hypertrophy, as a common element of SHR 
and RVH models of hypertension, predisposes the myocardium to the 
adverse effects of diabetes. The thyroid hormone deficit associated 
with diabetes, in both the SHR and RVH models of hypertension, may 
contribute to this myocardial dysfunction. Furthermore, since 
thyroid hormone treatment of diabetic SHR prevents impaired SR 
calcium uptake and action potential prolongation, attendant 
hypothyroidism may play a significant role in the etiology of 
diabetic cardiomyopathy in hypertrophic left ventricle. 
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PREFACE 
This dissertation was prepared according to the manuscript 
thesis plan. The first section of the dissertation consists of a 
general introduction and provides background information, rationale, 
hypotheses and specific aims for the following study. The second 
section consists of three manuscripts. The first two manuscripts are 
prepared according to the format of the journal Hypertension. The 
third manuscript is prepared according to the format of the American 
Journal Q.f Physiology. All three papers describe the cardiovascular 
effects of either insulin or thyroid hormone treatment in diabetic 
genetically hypertensive rats. The first paper provides detailed 
analyses of these effects on ventricular performance of isolated 
perfused working hearts. The second paper focuses specifically on 
myocardial relaxation of the working hearts and a biochemical 
2+ 
correlate to this function, Ca uptake by the sarcoplasmic 
reticulum. The third paper characterizes the effects of diabetes and 
thyroid hormone treatment on ventricular action potentials in the 
hypertensive rat. 
Section three of the dissertation is a general discussion that 
encompasses all of the results obtained in each of the three studies 
listed above along with data presented in Appendix A. Appendix A 
details the effects of diabetes on cardiac performance in another 
experimental model of hypertension, the renovascular hypertensive 
rat. Appendix B provides the computer programs that were developed 
and used to acquire the data for most of the analyses. The last 
section is a bibliography for the entire dissertation. 
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GENERAL INTRODUCTION 
Cardiovascular disease contributes significantly to morbidity 
and mortality in the diabetic population (for review see Dillmann 
1989). The incidence of coronary artery disease ·(such as 
atherosclerosis) and congestive heart failure (CHF) is 2 - 5 times 
greater in the presence of diabetes than it is in the general 
population (Kannel et al. 1974). Cardiac functional abnormalities 
that are commonly associated with diabetes include decreases in 
ejection fraction and stroke volume and increases in left ventricular 
(LV) end diastolic pressure and wall stiffness (Hamby et al. 1974; 
Regan et al. 1977). Impaired diastolic f~lling may be the first 
clinical sign of diabetes-induced cardiac dysfunction (Park et al. 
1988; Ruddy et al. 1988). In addition to coronary artery disease, 
the etiology of CHF in diabetes may also involve either an autonomic 
neuropathy or a specific cardiomyopathy or both (Kannel et al. 1974; 
Regan et al. 1977; Fisher et al. 1986; Sunni et al. 1986). Even in 
the absence of coronary vascular disorder, the frequency of CHF is 
still higher than expected in diabetic patients (Kannel et al. 1974; 
Regan et al. 1977). The term diabetic cardiomyopathy is used to 
define depressed heart mechanical performance that results from 
myocardial dysfunction independent of the coronary vasculature 
(Dhalla et al. 1985; Fein and Sonnenblick 1985; Dillmann 1989). 
Diabetic cardiomyopathy may be associated with specific cellular 
lesions. Studies using animals with chemically-induced diabetes 
(Penpargkul et al. 1980; Garber and Neely 1983) and animals which are 
genetically predisposed to diabetes (Lopaschuk and Tsang 1987; Brady 
and Brady 1989; Rodrigues and McNeill 1989) have been useful for 
-1-
determining specific areas of cardiomyocyte disruption. For example, 
diabetes promotes an increase in phospholipid incorporation in the 
plasma, sarcoplasmic recticular (SR), and mitochondrial membranes 
(Gudbjarnason et al. 1987; Lopaschuk and Tsang 1987; Makino et al. 
1987; Xiang et al. 1988; Black et al. 1989; Lopaschuk and Spafford 
1989). Decreases in specific enzyme activities (e.g., Na+/K+ ATPase 
2+ 
and Ca ATPase) and prolonged duration of the action potential (AP) 
are often correlated with this altered membrane composition (Fozzard 
and Arnsdorf 1986). These and other cellular changes can interfere 
with the heart's normal pump function. Diabetes depresses indices of 
mechanical performance in situ (Regan et al. 1974) and ex vivo 
(Penpargkul et al. 1980; Fein et al. 1983; Rodgers 1986). The 
diabetic heart generally exhibits lower ventricular pressure 
generation, decreased contractility and prolonged relaxation when 
compared to a normal heart (Garber and Neely 1983; Kobayashi and 
Neely 1983; Tahiliani and McNeil! 1984; Rodgers 1986). 
The risk of cardiovascular complications appears to be greater 
when diabetes is combined with hypertension both clinically and 
experimentally (Kannel et al. 1974; Factor et al. 1980, 1981; Drury 
1985; Fuller 1985; Rodgers 1986; Rodrigues and McNeill 1986; Sparafka 
et al. 1988; Bell 1989; Fein et al. 1989; Tzagournis 1989). 
Chemically-induced diabetes in hypertensive rats has a more profound 
effect on cardiac function than it does in normotensive 
(nonhypertensive) models (Fein et al. 1984; Rodgers 1986; Rodrigues 
and McNeil! 1986). For instance, histological and ultrastructural 
changes are more evident in the diabetic renovascular hypertensive 
(RVH) rat heart than in control rat hearts (Factor et al. 1980, 1981; 
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Fein et al. 1989). Diabetes depresses LV performance to a greater 
extent in the spontaneously hypertensive rat (SHR) than in the 
normotensive Wistar Kyoto (WKY) or Sprague-Dawley rat (Rodgers 1986). 
It may be the presence of preexisting LV hypertrophy, a consequence 
of elevated arterial pressu~e, that exacerbates the functional 
defects in diabetic myocardium (Factor et al. 1983). Hypertrophic 
muscle progresses from an adaptive phase, during which an increase in 
muscle mass benefits the heart by redistributing the increase in 
workload, to a compromised phase, during which force of contraction 
is significantly reduced (Pfeffer et al. 1979; Scheuer and Buttrick 
1987). Even when diabetes is induced in animals whose cardiac 
function is still well within the adaptive phase of hypertrophy, 
cardiac function subsequently is more severely impaired than it is in 
nonhypertrophic muscle (Rodgers 1986; Rodrigues and McNeill 1986). 
Since diabetes depresses systolic arterial pressure and can reverse 
LV hypertrophy in SHR (Rodgers 1986), neither sustained hypertension 
nor LV hypertrophy is required in order to manifest these 
cardiodepressive effects. Thus, LV hypertrophy may predispose the 
heart to the adverse effects of diabetes. 
Hypothyroidism, or a "low thyroid state", is often reported as a 
secondary metabolic disorder of diabetes (Pittman et al. 1979; Bagchi 
1982; Dillmann 1989), and insulin replacement therapy has been shown 
to restore normal thyroid status in diabetic rats (Garber et al. 
1983). Hypothyroidism and diabetes have a number of similar effects 
on cardiac metabolism and function. For example, both pathological 
conditions impair myocardial contractility, depress myosin ATPase 
activity and SR ca 2+ uptake (Suko 1973; Takacs et al. 1982; Morkin et 
-3-
al. 1983; Dhalla et al. 1985; Rodgers et al. 1986), prolong the 
cardiac AP (Freedberg et al. 1970; Nordin et al. 1985; Sauviat and 
Feuvray 1986; Capasso et al. 1986; Binah et al. 1987) and reduce 
sensitivity to adrenergic agonists (Bilezikian and Loeb 1983; 
Gotzsche 1986). Whether the cardiovascular effects of diabetes are 
at least in part due to the attendant hypothyroid state has been 
addressed in a number of studies (Tahiliani and McNeil! 1986). 
Thyroid hormone replacement therapy in normotensive diabetic rats has 
been shown to be either ineffective (Tahiliani and McNeil! 1984; 
Tahiliani and McNeill 1985; Barbee et al. 1988) or only partially 
effective (Garber et al. 1983; Goyal et al. 1987) in restoring 
cardiac function and atrial AP configuration (LeGaye et al. 1988). 
The prevailing view up to now is that the attendant hypothyroidism 
does not play a significant role in diabetic cardiomyopathy in the 
absence of hypertension (Tahiliani and McNeil! 1986; Dillmann 1989). 
Indirect evidence, however, suggests that the influence of an 
imbalance in thyroid status on the cardiovascular system may have a 
greater impact in the diabetic SHR than it does in diabetic 
normotensive strains. Thyroidectomy (Tx) of young SHR prevents the 
onset of elevated systolic arterial pressure (Rioux and Berkowitz 
1977), and either Tx or methimazole treatment of SHR decreases 
contractility and pressure generation of the isolated working heart 
(Rodgers 1986; Rodgers and McNeil! 1986). These effects of 
hypothyroidism in the SHR strain are reminiscent of, but less 
pronounced than, those of diabetes (Rodgers 1986). 
A common manifestation of diabetes and hypothyroidism is reduced 
2+ 
rate of Ca uptake by the SR (Suko, 1973; Penpargkul, 1981). This 
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biochemical impairment is closely associated with depressed rates of 
myocardial relaxation in both diabetes (Penpargkul et al. 1980; 
Penpargkul et al. 1981) and hypothyroidism (Rodgers and McNeill 
1986). Load-dependent relaxation of cardiac muscle is dependent upon 
the activity of SR in order to lower intracellular free ca 2+ 
concentrations (Brutsaert et al . 1980; Bers 1987). The adverse 
effects of diabetes on indices of relaxation do not appear to be 
dependent on thyroid state in nonhypertrophic muscle (Tahiliani and 
HcNeill 1984). While the effects of LV hypertrophy on SR ca 2+ uptake 
and relaxation of heart muscle are not consistent (Limas and Cohn 
1977; Capasso et al. 1986; Rodgers et al. 1986; Cuneo and Grassi de 
Gende 1988), the combined effects of diabetes and LV hypertrophy are 
more pronounced on isometric relaxation of RVH rat papillary muscle 
(Fein et al. 1984). The interaction of diabetes and LV hypertrophy 
myocardial relaxation and SR ca2+ uptake have not been investigated. 
The cardiac AP configuration is similarly altered by the effects 
of either diabetes or hypothyroidism (Aronson and Keung 1983; Fein et 
al. 1983; Nordin et al. 1985; Capasso et al. 1986; Capasso et al. 
1986; Sauviat and Feuvray 1986). Prolongation of the cardiac AP is 
the most consistent consequence common to these abnormalities, and 
may be functionally related to associated mechanical alterations 
which are also characteristic of each condition. The presence of 
hypertrophy alone is not always associated with changes in AP 
configuration. The etiology and duration of the hypertrophy may 
influence the extent of the electrophysiological changes. Neither 
right ventricular hypertrophy in cat (Kaufmann et al. 1971) nor 
papillary muscle hypertrophy in SHR (Volkmann et al. 1989) 
-5-
significantly prolong the cardiac AP when compared to nonhypertrophic 
controls. However, the hypertrophy of RVH papillary muscle prolongs 
AP duration (Aronson 1980) and this increase is magnified in a time 
dependent manner (Capasso et al. 1986). A combin'ation of any of 
these disease states (diabetes, hypothyroidism or hypertrophy) may 
have additive effects on ventricular transmembrane potentials (Fein 
et al. 1984; LeGaye et al. 1988), as they seem to have on mechanical 
function (Fein et al. 1984; Rodgers 1986; Rodrigues and HcNeill 
1986). 
Ventricular muscle contraction begins with the depolarization of 
the sarcolemma. The influx of calcium ions during the AP appears to 
trigger the release of additional ca 2+ from the SR, raising 
intracellular free ca 2+ levels and promoting contraction (Fabiato and 
Fabiato 1979). Changes in membrane potential properties can 
therefore alter mechanical activities. Too much or too little 
intracellular free ca2+ is detrimental to cell function (Dhalla et al 
1985; Morad and Cleemann 1987). The accumulative effects of 
2+ prolonged AP duration and lower rates of Ca uptake may be to 
increase intracellular free ca 2+ concentrations, reduce ca 2+ 
dissociation from the contractile filaments, and lead to depressed 
rates of myocardial relaxation. The interaction of these and other 
cellular events provide the basis for the experimental design of the 
following studies. 
-6-
The working hypotheses of this study, and their rationales, are 
listed below. 
1) Thyroid hormone treatment of diabetic SHR will at least partially 
prevent the decline in cardiac performance affected by chronic 
(8 weeks) diabetes mellitus. Depressed cardiac function in 
thyroidectomized SHR is similar to, but not as severe as in 
diabetic SHR (Rodgers 1986; Rodgers and McNeill 1986). 
Furthermore, thyroidectomy as well as diabetes depresses 
systolic arterial pressure in SHR (Rioux and Berkowitz 1977; 
Rodgers 1986). The cardiodepressive effects of diabetes in SHR 
may in part be influenced by a low thyroid state. 
2) Chronic diabetes should impose a more pronounced impairment in the 
2+ 
rate and extent of LV relaxation and SR Ca uptake in the SHR 
than it will in nonhypertrophic, nonhypertensive rats. A common 
physiological consequence of either hypertrophy or diabetes is 
impaired myocardial relaxation (Fein et al. 1980; Penpargkul et 
al. 1980; Capasso et al. 1986). The combination of diabetes and 
hypertrophy has a greater detrimental effect on myocardial 
relaxation than does either disease state alone (Fein et al. 
1984; Rodrigues and McNeill 1986). Some studies have reported 
2+ depressed rates of SR Ca uptake in both hypertrophic and 
diabetic heart muscle (Limas and Cohn 1977; Penpargkul et al. 
1981). The adverse effects of diabetes on LV relaxation and SR 
2+ Ca uptake may be greater in hypertrophic than in 
nonhypertrophic myocardium. 
3) Thyroid hormone treatment of diabetic SHR will at least partially 
-7-
2+ prevent the decline in LV relaxation and SR Ca uptake affected 
by chronic diabetes mellitus. Like diabetes, hypothyroidism i s 
associated with impaired myocardial relaxation and depressed 
rates of ca 2+ sequestration by the SR (Suko 1973; Penpargkul et 
al. 1980; Penpargkul et al. 1981; Takacs et al. 1982; Rohrer and 
Dillmann 1988). The hypothyroidism that attends diabetes may 
influence indices of myocardial relaxation in SHR. 
4) Chronic diabetes will prolong the ventricular AP to a greater 
extent in SHR than in nonhypertrophic, nonhypertensive rats. A 
common electrophysiological effect of diabetes and some models 
of hypertrophy is the prolongation of the cardiac AP (Gulch et 
al . 1979; Aronson and Keung 1983; Fein et al. 1983; Nordin et 
al. 1985; Thollon et al. 1985; Sauviat and Feuvray 1986; 
Volkmann et al. 1989). Diabetes exacerbates the prolonged AP in 
the hypertrophic RVH ventricular AP (Aronson 1980; Fein et al. 
1984). Diabetes may have a more pronounced effect on AP 
duration in SHR papillary muscle when compared to WKY muscle . 
. 5) Thyroid hormone treatment of diabetic SHR will at least 
partially prevent the diabetes-induced prolongation of the 
ventricular AP. Either diabetes or hypothyroidism alone, 
prolongs the ventricular AP in nonhypertensive rats (Capasso et 
al. 1986; Sauviat and Feuvray 1986). Thyroid hormone treatment 
prevents some of the AP configurational changes of atrial muscle 
in diabetic rats (LeGaye et al. 1988). 
6) Chronic diabetes will depress LV performance in isolated RVH rat 
hearts to a greater extent than in hearts from normotensive 
rats. LV function is profoundly depressed in isolated working 
-8 -
hearts of diabetic SHR (Rodgers 1986; Rodrigues and McNeill 
1986) . Diabetes may impair isometric relaxation in RVH 
papillary muscles more so than i n nonhypertensive, 
nonhypertrophic muscles (Fein et al. 1983; Fein et al. 1984). 
Hypertrophy, regardless of the etiology, may predispose the 
myocardium to the adverse mechanical effects of diabetes. 
7) Thyroid hormone treatment of RVH rats will at least partially 
prevent the cardiodepressive effects of diabetes. This last 
study will be conducted primarily to ascertain whether the 
cardiac impairments seen in the diabetic SHR isolated heart and 
the effectiveness of T3 treatment on heart performance, is 
independent of the etiology of hypertension in the rat. 
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The specific aims of the study are as follows: 
1) LV performance of SHR will be evaluated using an isolated perfused 
working heart preparation (Rodgers 1986). Diabetes will be 
chemically induced and certain animals will be chronically 
treated with either insulin or thyroid (T 3) hormone. Various 
other control groups will be included in order to identify 
contributing factors that may be secondary to diabetes. For 
example, to assess the cardiovascular effects of malnutrition 
and non-specific effects of the diabetogenic agent 
streptozotocin, food restriction and pretreatment with 
3-0-methylglucose (Ramanadham et al. 1987) will be employed, 
respectively. T3-treated nondiabetic SHR will also be included. 
2) A detailed examination of ventricular relaxation and a biochemical 
2+ 
correlate, SR Ca uptake by isolated LV microsomes, will be 
analyzed in both SHR and normotensive WKY. These indices of 
relaxation will be evaluated in hearts from diabetic and 
nondiabetic animals with or without insulin or T3 treatment. 
3) Resting membrane potential and AP will be recorded from papillary 
muscle fibers of normal and diabetic SHR and WKY, and insulin-
or T3- treated diabetic SHR. 
4) The effects of diabetes and hormone treatment upon cardiac 
performance will be assessed in isolated working hearts of RVH 
rats. Control groups similar to those described for the SHR 
study (11 above) will be included. 
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Insulin, Thyroid Hormone and Heart Function 
of Diabetic Spontaneously Hyp~rtensive Rat 
-11-
SUMMARY 
Diabetes impairs cardiac performance more extensively in 
hypertensive rats than it does in nonhypertensive strains. A "low 
thyroid state" may contribute to the adverse cardiovascular effects 
of diabetes in the spontaneously hypertensive rat (SHR). We tested 
this hypothesis by comparing the effects of thyroid hormone with 
those of insulin treatment on cardiac performance of diabetic SHR. 
Diabetes was induced with streptozotocin (45 mg/kg). Subsets of 
diabetic animals were treated with either insulin (10-20 U/kg/day) or 
triiodothyronine (8-10 µg/kg/day). Heart rate and systolic arterial 
pressure were obtained at weekly intervals. After eight weeks, 
cardiac function was assessed using an isolated working heart 
preparation. Diabetes reduced arterial pressure and heart rate in 
vivo, and markedly depressed cardiac performance under volume and 
pressure loading conditions ex vivo, confirming previous 
observations. As expected, insulin treatment prevented the 
bradycardia and depressor effect in vivo, and the impairment of 
cardiac performance ex vivo caused by diabetes. The triiodothyronine 
treatment duplicated the effects of insulin on the hemodynamic 
measurements in vivo, and corrected nearly all depressed indices of 
performance of diabetic SHR hearts ex vivo. Both treatment regimes 
successfully reduced eight-week mortality when compared with the 
untreated diabetic group. The results support the hypothesis that a 
low thyroid state may contribute to the cardiovascular dysfunction in 
diabetic SHR. Left ventricular hypertrophy may be an important 
factor in this phenomenon. 
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INTRODUCTION 
Diabetes mellitus is associated with cardiac impairments in 
humans1 and in experimental animals 213 Both clinical and 
experimental "diabetic cardiomyopathy" may be exacerbated by 
hypertension 4 Chemically induced diabetes in hypertensive rats has 
a more profound effect on cardiac function than it does in 
normotensive models 5- 7 . Collectively, the data suggest that pressure 
load-induced left ventricular hypertrophy increases the 
1-7 
susceptibility of the myocardium to diabetes related derangements 
Hypothyroidism, or a "low thyroid state", is often reported as a 
secondary metabolic disorder of diabetes 8, and insulin replacement 
therapy has been shown to restore normal thyroid status in diabetic 
9 
rats . Hypothyroidism and diabetes have a number of similar effects 
on cardiac metabolism and function. For example, both pathological 
conditions impair myocardial contractility, depress myosin ATPase 
t . •t d 1 . t• 1 2+ t k 10 - 12 d d ac iv1 y an sarcop asm1c re icu ar Ca up a e , an re uce 
sensitivity to adrenergic agonists13 Whether the cardiovascular 
effects of diabetes are at least in part due to the attendant low 
thyroid state has been addressed in a number of studies. Thyroid 
hormone treatment of normotensive diabetic rats has been shown to be 
"th . ff t• 14115 1 t• 11 ff t• 9 . t . e1 er ine ec ive or on y par ia y e ec ive in res or1ng 
cardiac function. 
Indirect evidence suggests that the influence of an imbalance in 
thyroid status on the cardiovascular system may have a greater impact 
in the diabetic spontaneously hypertensive rat (SHR) than it does in 
diabetic normotensive strains. Thyroidectomy (Tx) of SHR prevents 
. 16 17 the onset of elevated systolic arterial pressure (SAP) ' , and 
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either Tx or methimazole treatment decreases contractility and 
pressure generation of the isolated working heart 6117 These effects 
of hypothyroidism in the SHR strain are reminiscent of, but less 
pronounced than, those of diabetes 6 
The following investigation was designed to assess the impact of 
the attendant hypothyroidism on cardiac function in the diabetic SHR 
by comparing the effects of triiodothyronine (T3) treatment with 
those of insulin therapy. The results add support to the hypothesis 
that attendant hypothyroidism contributes to the adverse cardiac 
effects of diabetes in the SHR. 
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METHODS 
Animal Groups . Male SHR were obtained from Charles River Breeding 
Laboratories (Wilmington, MA), housed communally and fed ad libitum 
unless otherwise indicated . At 15 weeks of age animals were weight 
matched and earmarked for either nondiabetic or diabetic groups. 
Diabetes was induced with a single tail vein injection of 
streptozotocin (STZ), 45 mg/kg bw (Sigma Chemical Co., St. Louis, MO) 
after animals were lightly etherized. The STZ was dissolved in 
citrate buffer (0.1 Hat pH 4.5) just prior to use. A subset of 
animals was first injected with 3-0-methylglucose (OMG; 1.2 mmol/150 
g BW), followed by STZ within one minute 18 . Animals in the 
nondiabetic groups were also etherized and given similar volumes of 
the citrate buffer alone. Urine glucose levels were estimated using 
DIASTIX(R) (Ames, Elkhart, IN). Diabetes was confirmed in all 
animals that received STZ. No urinary glucose was detected in the 
OMG group. 
The following treatment regimes were begun three days after the 
tail vein injections. Diabetic animals were further divided into 
four subgroups and were treated with one of the following: Lente 
insulin (LI; Sigma), 20 U/kg/day s.c.; protamine zinc insulin (PZI; 
Eli Lilly Co., Indianapolis, IN), 10 U/kg/day s.c.; or T3 (Sigma), 
8-10 ug/kg/day s.c. The fourth group of diabetic animals remained 
untreated for the duration of the experiment. A preliminary study 
was conducted in order to determine an appropriate T3 dose in 
diabetic SHR19 . An initial T3 dose of 30 µg/kg/day
15 
resulted in 
elevated systolic arterial pressure and heart rate compared to 
untreated nondiabetic animals. The T3 dose was subsequently reduced 
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to 10 µg/kg/day and readjusted to 8 µg/kg/day after 6 weeks so that 
heart rates of the treated, diabetic animals matched those of the 
nondiabetic controls (see Figure lB). The nondiabetic animals were 
also subdivided: untreated; food restricted (FR)j or T3, 8-10 
µg/kg/day s.c. The FR animals were housed individually, and their 
food allowance was adjusted so that their weights were similar to 
those of the untreated diabetic group. 
In Vivo Measurements. Weekly measurements of SAP, heart rate (HR) 
and body weight (BW) were taken just prior to the tail vein 
injections and then for eight subsequent weeks. SAP and HR were 
obtained in triplicate using standard tail-cuff sphygmomanometry, 
after the animals were placed in a temperature controlled chamber 
(34°C) for 10-15 minutes. These measurements were recorded before 
the daily injections of r 3 or insulin, and after the food restricted 
group was fed. 
Serum Assays. The animals were killed by rapid decapitation eight 
weeks after the STZ or citrate buffer injections. The serum samples 
were collected 15-18 hours subsequent to the final insulin or T3 
injection, and stored at -2ooc for future determinations. The degree 
of diabetes was assessed by serum glucose values using a glucose 
oxidase assay (Sigma). Animals were considered diabetic if serum 
glucose concentrations exceeded 300 mg/dL. Serum immunoreactive 
insulin activity, total T3 and total thyroxine (T 4l were determined 
by radioimmunoassay (Cambridge Medical Diagnostics, Billerica, MA). 
Serum levels of insulin were quantified using rat insulin (generously 
provided by Dr. R. Chance of Eli Lilly, Inc.) as a standard. 
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Cardiac Performance. The hearts were quickly removed and perfused as 
described previously6 In brief, the perfusion apparatus was 
designed to allow manipulations in both volume loading (left atrial 
filling pressure, LAFP) and pressure loading (resistance to aortic 
ejection). Left ventricular pressure (LVP) and aortic pressure (AP) 
were monitored continually through indwelling cannulae coupled to 
pulse transducers (Stratham, Hato Rey, PR). Aortic flow rate (AFR) 
and coronary flow rate (CFR) were quantified intermittently. 
Myocardial oxygen consumption (V0 2l was assessed with an in-line o2 
electrode (Transidyne Corp., Ann Arbor, HI) confluent with the 
coronary perfusate (see calculations below). 
Hearts were perfused with nonrecirculating Krebs-Henseleit 
buffer maintained at 37oc. The buffer contained 120 mH NaCl, 5.6 mH 
KCl, 0.65 mH MgS0 4, 1.21 mH NaH 2Po 4, 25 mH NaHC0 3, 2.4 mH CaC1 2, 0.2 
mH EDTA and 10 mH glucose (pH 7.4 when gassed with 95\ o2 and 5% 
co 2J. Bipolar electrodes (attached to a Grass SD9 Stimulator; Grass 
Instruments, Quincy, MA) were placed on the right atrium, and hearts 
were paced at 300 beats per minute. Occasionally, endogenous 
rhythmicity exceeded 300 bpm at which time external pacing was 
discontinued. The data were continually recorded on a chart recorder 
(Narco Trace Hodel 80; Narco Biosystems, Houston, TX) and a 
dedicated computer (Buxco Corp., Sharon, CT). LVP waves were also 
recorded and stored in an IBM PCII using ASYST(R) software (Macmillan 
Software Co., New York, NY) and A/D conversion hardware (Data 
Translation Inc., Marlborough, MA). To ensure the stability of each 
preparation, LVP generation was monitored prior to data collection 
for 10-15 minutes while LAFP was set at 15 cm H2o and resistance to 
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aortic ejection was set at 1.54 kPa/cm3.min-1 . Measurements were 
first recorded during volume loading at LAFPs of 5, 10, 15, and 20 cm 
H2o while holding resistance constant at 1.54 kPa/cm
3
.min-1 . They 
were then recorded during pressure loading at aortic resistances of 
0.19, 0.41, 1.54 and 3.13 kPa/cm3 .min-l while holding LAFP at 15 cm 
H2o. Total perfusion time rarely exceeded 30 minutes. 
Heart Weight Ratios. Once the data were collected, the hearts were 
removed from the perfusion apparatus and blotted dry. The aorta was 
removed, and the following wet weights were obtained; whole heart 
(HW), left ventricular (LV) including the septum, and right 
ventricular (RV). These weights were used to assess the degree of 
left ventricular hypertrophy6 
Calculations. Direct measurements included LVP, left ventricular 
end-diastolic pressure (EDP), AFR, CFR, aortic pressures (including 
mean aortic pressure (MAP)), and po2 of the coronary effluent. 
Indices of heart performance included left ventricular pulse pressure 
(LVPP as maximum LVP minus EDP), maximum rate of left ventricular 
pressure generation (LV + dP/dt), hydraulic power (power as the 
product of LVPP and cardiac output (CO=AFR plus CFRJ per gram HW) and 
stroke work (SW as the ratio of power to HR). Myocardial oxygen 
consumption (V0 2) was calculated as the product of oxygen extracted 
from the buffer, CFR and oxygen solubility in buffer at 37°c (31.25 
µL/cm 3) and normalized for HW. The efficiency of contraction (E) was 
then calculated as the ratio of power to vo 2. Coronary vascular 
resistance (CVR) was estimated from the slope of the regression line 
when MAP was plotted against CFR at the four pressure loads 6. 
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Statistical Analyses. The differential effects of diabetes and the 
hormone treatments were evaluated by analysis of variance (with 
repeated measures where appropriate), and the Student Newman-Keuls 
test for multiple comparisons (Statistical Analysis System, Cary, 
NC). Group means were considered statistically different ·from each 
other if the probability value was less than 0.05. Lower 
probabilities were not reported. All group comparisons were made 
statistically; however, in most cases it was only necessary to 
present comparisons of each experimental group to the untreated, 
nondiabetic SHR. Additional comparisons, between experimental 
groups, were noted only if they had obvious relevance to the 
discussion. 
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RESULTS 
Serum Assays. Serum glucose levels were elevated in all STZ-injected 
groups except those which had been pretreated with OHG (Table 1). 
Treatment with PZI controlled the hyperglycemia more effectively than 
LI did, but neither treatment restored serum glucose levels to that 
of the nondiabetic animals. Glucose levels of the FR and T3-treated 
nondiabetic SHR were not different from those of the untreated, 
nondiabetic group. 
Hypoinsulinemia was evident in both the untreated and the 
T3-treated diabetic rats. Both PZI and LI treatments markedly 
elevated serum immunoreactive insulin activity; PZI effected the most 
pronounced increase. The elevated levels may reflect a 
subsensitivity to exogenous insulin in the diabetic rat. The serum 
insulin levels of all the other groups were normal. 
Diabetes also reduced serum T3 and T4 levels. Either insulin or 
T3 treatment prevented the decline in T3 concentration. Insulin 
treatment also reversed the drop in T4 levels. However, T3 treatment 
of either diabetic or nondiabetic SHR markedly suppressed serum T4 
concentrations. The OMG and FR groups had normal T3 values but the 
FR group had slightly depressed T4 levels. 
Body and Heart Weights. Diabetes reduced both heart and body weights 
of SHR (Table 2). Treatment with PZI completely prevented these 
changes, whereas LI was only partially effective. In contrast, T3 
therapy did not affect the decline in HW, but increased the extent of 
the loss in BW, of diabetic SHR. Administration of T3 to nondiabetic 
SHR had no effect on BW or HW. The effects of STZ-induced diabetes 
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on BW and HW were nearly duplicated by food restriction, and 
completely blocked by OMG pretreatment. 
The ratios HW/BW and LV/BW, which are indices of relative 
cardiac hypertrophy, and LV/RV, which is an index of absolute left 
6 
ventricular hypertrophy , were not significantly affected by any of 
the experimental manipulations except one; the extent of relative 
hypertrophy was increased in the T3-treated diabetic group. 
Mortality. The mortality rate of the diabetic SHR was about 64%, 
which was much higher than that of any other group (Table 3). As 
expected, insulin treatment (either PZI or LI) prevented the eight 
week mortality of diabetic SHR. Unexpectedly, T3 treatment was as 
effective as insulin was in preventing (or delaying) mortality of the 
diabetic animals. The mortality in the FR group occurred early in 
the study, as a result of attempts to exactly duplicate the mean BW 
of the diabetic group. Slight upward adjustments of the food 
allotment prevented further mortality, and resulted in mean BW which 
was slightly higher than that of the diabetic group by the end of the 
eight week period (see Table 2). The mortality of diabetic SHR was 
completely prevented by treatment with OMG prior to STZ injection. 
Systolic Arterial Pressure and Heart Rate. Diabetes depressed SAP of 
SHR in. vivo, beginning about four weeks after STZ injection (Figure 
lA), confirming previous results6 It also caused a progressive 
decline in HR (Figure 18). Either insulin (PZI or LI) or T3 
treatment prevented both the depressor and bradycardic effects of 
diabetes. Since both PZI and LI restored SAP and HR to control 
values, the two insulin-treated groups were pooled in Figure 1 and 
Table 4. A summary of the SAP and HR measurements in the remaining 
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control groups at the eight week time point is provided in Table 4. 
With one exception, none of these values is significantly different 
from that of the untreated, nondiabetic group. Only the HR of the FR 
group was significantly depressed. 
Cardiac Performance Ex Vivo. Diabetes impaired the performance of 
SHR hearts ex vivo, under either volume- or pressure-loading 
conditions (Figures 2 and 3). The impairment was evident as a 
decline in LVPP and SW at higher volume loads (Figure 2), and in LVPP 
at higher pressure loads (Figure 3). Diabetes also depressed left 
ventricular contractility (LV + dP/dt; Table 5). These results 
generally confirm those of previous reports 617 , which had also 
demonstrated that the magnitude of the cardiac impairment due to 
diabetes is greater in the SHR than it is in normotensive rats. Both 
insulin treatments of diabetic SHR (either PZI or LI) completely 
prevented the decline in cardiac performance; in the interest of 
clarity, therefore, the data for the two insulin-treated groups were 
pooled in Figures 2 and 3 and in Tables 5-7. Treatment of diabetic 
SHR with T3 was nearly as effective as was insulin therapy (Figure 
4); it completely prevented all effects of diabetes except that it 
only partially maintained LVPP at the highest volume load (Figure 2A 
and Table 5) and depressed LVPP at the lowest pressure load (Figure 
3A). In addition, T3 treatment of diabetic animals significantly 
increased SW at a LVFP of 10 cm H2o (Figure 28). Neither LVPP, SW, 
nor contractility of any of the other control groups was different 
from the corresponding value of the nondiabetic control under either 
volume-loading (Table 5) or pressure-loading conditions (data not 
shown). Thus, neither malnutrition nor direct cardiotoxic effects of 
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STZ appear to contribute significantly to the cardiac impairments of 
the diabetic SHR. 
Diabetes had no effect on vo2, co, hydraulic power, or 
efficiency of contraction (E; Table 6). None of the experimental 
groups differed significantly from the control with regard to any of 
these variables, except that the CO (per gram HW) of the T3-treated 
diabetic group was elevated. This was related more to the reduction 
in heart size than it was to any increase in total output 20 
Although diabetes reduced total coronary flow rate (CFR), it had 
no effect on either CFR per gram HW or on CVR (Table 7). Thus, the 
impaired LVPP, SW and contractility of diabetic SHR hearts were not 
associated with restricted coronary flow. 
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DISCUSSION 
Recent results from this laboratory suggested that a low thyro i d 
state might contribute significantly to changes in cardiac 
performance of diabetic SHR 6117 . Accordingly, we expected that T3 
treatment of diabetic SHR might reduce the magnitude of the 
subsequent impairment in mechanical function. We were somewhat 
surprised, though, that the dose of T3 used in this study was almost 
as effective as insulin was in preventing the depressions in 
measurements of heart function, including pressure generation, rates 
of contraction, and stroke work. 
Our results obtained from SHR differ from previous reports of 
the effects of T3 treatment on cardiac function and hemodynamic 
t . d. b t· t . t 9,14,15 measuremen s in ia e ic normo ens1ve ra s . In the earlier 
studies, T3 treatment - at doses ranging from approximately 8 to 30 
µg/kg/day - was either ineffective or partially effective in 
preventing diabetes-induced myocardial functional impairments. For 
the present study, we selected the dose of T3 according to its 
ability to maintain normal HR in vivo, an index which is a sensitive 
indirect indicator of thyroid status. This turned out to be about 
2-3 fold greater than "physiologic" replacement doses in 
nonhypertensive rat strains 21 . The T3 dose used herein did not 
appear, however, to impose a hyperthyroid condition in diabetic SHR 
for several reasons: 1) It did not elevate serum T3 levels above 
normal, when measured at the same time point after injection, in 
either the diabetic or the nondiabetic SHR groups (Table l); 2) The 
22 
same dose given to nondiabetic SHR (Table 4) or to diabetic SD rats 
had no effect on SAP or HR in vivo; and 3) T3 treatment of 
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nondiabetic SHR had no effect on any of the indices of cardiac 
performance ex vivo (Tables 5- 7). Although T3 treatment reduced body 
weights of the diabetic SHR, it had no effect on this measurement in 
the nondiabetic control group (Table 2) . It may not be appropriate 
to assume that doses of T3 which are adequate for therapy of simple 
hypothyroidism should be enough to correct the hypothyroid state 
induced by diabetes. Diabetic hypothyroidism in the rat is 
characterized not only by low serum hormone levels, but also by 
target tissue resistance. For example, diabetes impairs peripheral 
T4 to T3 conversion, tissue T3 uptake, and both affinity and density 
of nuclear T3 receptors
23124 
The differences in the effects of T3 treatment between the SHR 
and normotensive diabetic rats are probably related to the elevated 
arterial pressure of SHR, and not to differences related specifically 
to the genetic strain. We have preliminary results (unpublished 
observations) that T3 is as effective in the diabetic renovascular 
hypertensive (RVH) rat as it is in the diabetic SHR. A common 
feature of the two models, left ventricular hypertrophy (LVH), may 
increase cardiac susceptibility to a number of stresses including 
th · db d. b t 41617 h th ·d· 12 · h · 25 ose impose y ia e es , ypo yro1 ism , or isc aem1a 
Our results suggest that the hypothyroidism accompanying diabetes has 
a more profound cardiovascular effect in animals with elevated 
arterial pressure, and that hypertrophied myocardium may be 
functionally more dependent upon thyroid status than is 
nonhypertrophic heart muscle. This hypothesis is supported by the 
observation that thyroidectomy reduces left ventricular contractility 
to a greater extent in the SHR than it does in the WKY17 . 
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There are a number of mechanisms by which T3 treatment might 
effectively reverse the cardiac functional impairments of diabetes, 
especially of hypertrophic heart muscle. A common manifestation of 
diabetes, hypertrophy and hypothyroidism on rat ventricular muscle is 
a shift from the predominant v1 to the v3 myosin 
isozyme9111121126 - 28 The effects of hypertension and diabetes (with 
or without hypothyroidism) on myosin isozyme profiles may thus be 
additive, but this hypothesis has not been tested. T3 treatment of 
the diabetic SHR may change the ratio of myosin isozyme activity in 
favor of v1 and this may in turn help to explain the increased left 
ventricular contractility in this group (Table 5). Another 
biochemical change frequently observed in hearts from either 
diabetic, hypertensive or hypothyroid animals is depressed 
sarcoplasmic reticular (SR) ca2+ uptake, which correlates with 
. . d d" 1 t t· d 1 t · io,12,2a impa1re myocar ia con rac ion an re axa ion Although 
thyroid hormone treatment did not restore SR ca 2+ uptake of diabetic 
normotensive rats15129 , its effectiveness on diabetic hypertensive 
muscle has recently been demonstrated (see accompanying manuscript). 
Metabolic derangements in the diabetic heart include decreased 
glucose utilization and increased lipid accumulation 30 These in 
turn have been linked to changes in energy substrate availability and 
membrane integrity and function in the heart 10 Hypertrophy may 
exacerbate these metabolic effects. Increased vulnerability of 
hypertrophic myocardium to metabolic stress may be related either to 
a lower energy state 31 or to abnormal lipid metabolism in the 
SHR7132 - 34 • Interestingly, the vasodilator hydralazine reduced serum 
lipids and improved cardiac function but also corrected the attendant 
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hypothyroid state in diabetic nonhypertensive rats 35 . Thyroid 
hormone may relieve some of these stresses in diabetic SHR, perhaps 
by i ncreasing the utilization of fatty acid by the myocardium36 , by 
stimulating glucose uptake and utilization 37 , or by augmentating 
1 . d d . l' t ' 38 1th h d t (T bl 1) di'd g ucose-1n uce insu in secre ion , a oug our a a a e 
not support the latter possibility. Thyroid hormone may also enhance 
the responsiveness of the myocardium to sympathoadrenal influences 
(see below) . 
Several alternative interpretations of our results could be 
eliminated by the control studies. Amelioration of the 
cardiodepression and mortality by either insulin or T3 treatment, and 
18 by pretreatment with the glucose analog OMG , ruled out the 
possibility that direct cardiotoxicity of STZ contributed to the 
morbidity and mortality of diabetes. Complete glycemic control was 
not necessary for preservation of cardiac functional activity, 
supporting previous · observations 34139 , both PZI and LI maintained 
pump function without normalizing serum glucose values (Table 1) . 
Malnutrition alone could not account for the observed 
cardiodepressive effects of diabetes in our study, since performance 
was not impaired in the food restricted group (Tables 5 and 6; see 
also references 3 and 6). 
Hypothyroidism probably also contributes to the reduction in SAP 
in vivo of diabetic SHR6 (Table 4). Thyroidectomy prevents the 
development of hypertension in this mode1 16117 , whereas T3 treatment 
of diabetic SHR prevents the decline in SAP (Table 4). The latter 
result also illustrates that the restorative effects of r 3 (and 
insulin) treatment are manifest in the face of sustained elevations 
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in arterial pressure load. The depressor effect of diabetes in SHR 
likely involves both vascular and cardiac components. Yamamoto and 
Nakai 40 seemed to show in their Table 3 that moderate diabetes 
reduced total peripheral resistance of SHR by about 10-20%, depending 
on the duration of diabetes . Administration of T3 may increase TPR 
in the diabetic SHR. On the other hand, variations in SAP of either 
diabetic or hypothyroid SHR, whether treated or untreated, always 
seem to be associated with parallel changes in cardiac 
6 7 17 performance ' ' (Table 4 and 5). Tsujimoto and Hashimoto 41 
attributed most of the rise in SAP of T3-induced hyperthyroid rats to 
cardiac, rather than to vascular, effects of T3. 
Treatment with T3, like insulin, also corrected the bradycardia 
of diabetic SHR (Figure 18). The bradycardia associated with either 
diabetes or hypothyroidism has been attributed, at least in part, to 
d d d . 1 . t d . t" 1 t• 13142 epresse myocar ia responsiveness o a renerg1c s imu a ion 
Both hypertrophic 43 and diabetic 44 myocardium have been shown to 
possess a lower density of functional a-adrenoceptors, and both 
insulin and T3 may be involved in the regulation of cardiac 
8-adrenoceptor density. Insulin may act indirectly by restoring 
serum T3 levels. Depressed myocardial B-adrenoceptor numbers of 
diabetic SD rats were restored to normal with either insulin or T4 
treatment, while those of thyroidectomized diabetic rats were not 
affected by insulin treatment alone 45 . The chronotropic action of T3 
in vivo may also involve a direct effect of the hormone on pacemaker 
46 
cells • The available evidence implies that at least a significant 
portion of the bradycardia of experimental diabetes, in the presence 
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or absence of hypertension, can be attributed to the attendant 
hypothyroidism. 
In conclusion, the cardiac impairments associated with diabetes 
in the SHR can be prevented by either insulin or T3 treatment. To 
our knowledge this is the first account of a moderate dose of T3 
successfully restoring cardiac performance in experimental diabetes. 
In addition, T3 treatment, like insulin, prevented the fall in 
arterial pressure and bradycardia induced by diabetes in the SHR in 
vivo, and either reduced or delayed mortality. The results suggest 
that attendant hypothyroidism may play a more significant role in the 
development of impaired cardiac function in diabetic SHR than it does 
in normotensive rats. The possible contribution of left ventricular 
hypertrophy to this phenomenon remains to be studied. These results 
may have some clinical applicability. Whether or not hypertension 
occurs more frequently among diabetic patients 47 , it is generally 
regarded as an important risk factor for the higher cardiovascular 
1 47 
morbidity and mortality in this group ' The incidence of impaired 
thyroid function among diabetics may be as high as 30\, is most 
severe during poor metabolic control, and is most evident in IDDH 23 
While diabetic patients with hypothyroidism may be at increased risk 
of cardiovascular morbidity and mortality48 , this risk may be further 
intensified by hypertension. 
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TABLE 1. Serum glucose, insulin, triiodothyronine and thyroxine levels of 
nondiabetic, diabetic and treated SHR. 
Glucose 
Group n (mg/dll 
Nondiabetic 12 122 t 22 
Diabetic 9 540 t 61* 
T3-treated diabetic 9 578 t 87* 
LI-treated diabetic 7 546 t 116* 
PZI-treated diabetic 7 370 t 179** 
r3-treated control 7 115 t 12 
FR control 9 120 t 36 
OHG control 9 136 t 20 
Insulin 
(µU/mll 
56 t 25 
14 t 7* 
18 t 7* 
229 t 129** 
355 t 183** 
67 t 15 
42 t 29 
50 t 13 
T3 
(ng/dll 
94 t 17 
53 t 13* 
73 t 13 
77 t 15 
85 t 22 
88 t 26 
88 t 14 
87 t 23 
6.96 t 1. 53 
2.92 t 0.58* 
0.28 t 0.09** 
5.46 t 0.94 
5.49 t 1. 57 
0.34 t 0.12** 
4.36 t 1.31** 
5.87 t 1.01 
Values are means i SD, obtained 8 weeks after initiation of diabetes or 
treatment. r 3, triiodothyronine; T4, thyroxine; LI, lente insulin; PZI, 
protamine zinc insulin; FR, food restricted nondiabetic group; OHG 
3-0-methylglucose pretreated, STZ-injected group. *Significantly different 
from the nondiabetic group. **Significantly different from the nondiabetic and 
diabetic groups. 
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TABLE 2. Body and heart weights of nondiabetic, diabetic and treated SHR. 
aw HW HW/BW LV/BW LV/RV 
Group n (g) (mg) (mg/g) (mg/g) (mg/mg) 
Nondiabetic 12 324:t28 1370:tl32 4.24:t0.46 3.4l:t0.38 5.56:t0.81 
* * Diabetic 9 208:t20 907:t 85 4.38:t0.30 3.48:t0.24 5.25:t0.61 
** * * 
t 
T3-treated diabetic 9 179:t26 929:tl46 5.22:t0.69 4.ll:t0.59 4. 93t0. 51 
tt tt 
LI-treated diabetic 7 283:t24 1213tll2 4.29t0.25 3.4lt0.21 6.16:t0.56 
PZI-treated diabetic 7 312:t27 137l:t 83 4. 4l:t0. 36 3.60t0.32 5.40:t0.56 
T3 treated contol 7 300:t20 1406:t 75 4.72t0.55 3.79t0.49 5.44:t0.68 
** 
tt 
FR control 9 241!11 1064:tll2 4.4lt0.39 3.62t0.38 6.04:t0.77 
OMG control 9 328t24 1370t 94 4.19:t0.24 3.43:t0.21 6.16t0.56 
Values are means t SD, obtained 8 weeks after initiation of diabetes or 
treatment. BW, body weight; HW, heart weight; LV, left ventricular weight; RV, 
right ventricular weight; T3, triiodothyronine; LI, lente insulin; PZI, 
protamine zinc insulin; FR, food restricted nondiabetic group; OMG, 
• 3-0-methylglucose pretreated, STZ-injected group. Significantly different 
tt 
from the nondiabetic group. Significantly different from the nondiabetic and 
diabetic groups. 
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TABLE 3. Hortality of nondiabetic, diabetic and treated SHR . 
Group Fraction 
Nondiabetic 1/18 
Diabetic 21/33 
T3-treated diabetic 1/14 
LI-treated diabetic 1/10 
PZI-treated diabetic 1/10 
T3-treated control 0/12 
FR control 3/13 
OHG control 0/10 
s· Hor tali ty 
\ 
5.6 
63.6 
7.1 
10.0 
10.0 
0 
23 . 1 
0 
SThe values represent the proportion of animals which had died 
during the eight week study period. r 3, triiodothyronine; LI, 
lente insulin; PZI, protamine zinc insulin; FR, food restricted 
nondiabetic group; OHG, 3-0-methylglucose pretreated, STZ-injected 
group. 
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TABLE 4. Systolic arterial pressure and heart rate of nondiabetic, diabetic 
and treated SHR. 
SAP (kPa) HR (beats/min) 
Group n Week 0 Week 8 Week 0 Week 8 
Nondiabetic 12 24.0 t 3.7 26.7 t 2.9 385 t 47 401 t 34 
Diabetic 9 23.7 t 2.5 21.1 t 1. 9* 366 t 28 273 t 22* 
r 3-treated diabetic 9 24.8 t 1.9 24.4 t 4.1 407 t 46 413 t 37 
I-treated diabetic 14 23.7 t 1. 6 26.5 t 3.3 397 t 35 366 t 42 
T3-treated control 7 24 .0 t 1.1 30.0 t 3.5 405 t 33 429 t 60 
FR control 9 25.3 t 1.9 26.3 t 2.0 372 t 18 358 t 40 
OHG control 9 23.6 t 2.4 29.7 t 3.5 377 t 19 384 t 27 
Values are means i SD, obtained before (Week 0) and 8 weeks after initiation of 
diabetes or treatment. SAP, systolic arterial pressure; HR, heart rate; T3, 
triiodothyronine; I, PZI and Lente insulin; FR, food restricted nondiabetic 
group; OHG, 3-0-methylglucose pretreated, STZ-injected group. *Significantly 
different from the nondiabetic group. 
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TABLE 5. Left ventricular pulse pressure (LVPP), stroke work and contractility 
(LV+dP/dt) of SHR perfused hearts under various experimental 
conditions. 
Group n LVPP Stroke Work LV+dP/dt 
(kPa) (mJ/g) (kPa/sec) 
Nondiabetic 12 21. 6 t 1. 8 2.47 t 0.46 913 .t 124 
t t t 
Diabetic 9 15.5 t 1.8 1. 76 t 0.42 572 t 132 
... 
T3-treated diabetic 9 18.7 t 0.8 2.57 t 0.47 854 t 120 
I-treated diabetic 14 21.3 
.t 2.5 2.49 .t 0.48 851±177 
T3-treated control 7 23.3 !. 1. 9 2.76 + 0.31 1101 ±. 147 
FR control 9 20.0 t 2.3 2 36 t 0.66 802 ±. 162 
OHG control 9 23.5 t 2.9 2.48 t 0.56 917 ±. 139 
Values are means t SD, obtained 8 weeks after initiation of diabetes or 
treatment. Left atrial filling pressure was fixed at 20 cm H2o and resistance 
to aortic ejection was fixed at 1.54 kPa/cm3•min-1 . Values for LVPP and stroke 
work of the first four groups are also depicted in Figure 2. I-PZI or Lente 
insulin; T3, triiodothyronine; FR, food restricted nondiabetic group; OHG, 
• 3-0-methylglucose pretreated, STZ-injected group. Significantly different 
... 
from the nondiabetic group. Significantly different from the nondiabetic and 
diabetic groups. 
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TABLE 6: Myocardial oxygen consumption (V0 2l, cardiac output (CO), power and 
efficiency of contraction (El of nondiabetic, diabetic and treated SHR. 
vo 2 co Po11er E 
Group n -1 (µL0 2/sec•g ) 
3 -1 (cm /sec•g ) (mW/g) (mJ/µL0 2l 
Nondiabetic 12 4.78 t 0.81 0.49 t 0.08 9.30 t 1. 84 1. 94 t 0.21 
Diabetic 9 4.26 t 0.39 0.51 t 0.07 7.53 t 1. 50 1. 76 t 0. 24 
t 
T3-treated diabetic 9 6.24 t 1.68 0.64 t 0.12 11. 49 t 2.14 1.92 t 0.40 
I-treated diabetic 14 5.29 t 0.92 0.53 t 0.07 9.93 t 2.07 1. 88 t 0.27 
T3-treated control 7 5.98 t 1.15 0.53 t 0.06 11. 07 t 1.62 1.89 t 0.24 
FR control 9 6.16 t 2.12 0.52 t 0.13 9.58 t 2.98 1.58 t 0.31 
OHG control 9 4.83 t 0.88 0.43 t 0.07 8. 91 t 2.01 1.83 t 0.22 
Values are mean t SD, obtained 8 11eeks after initiation of diabetes or 
treatment. Left atrial filling pressure 11as fixed at 15 cm H2o and resistance 
to aortic ejection was fixed at 1.54 kPa/cm3•min-1 • I-PZI and Lente insulin; 
T3, triiodothyronine; FR, food restricted nondiabetic group; OHG, 
3-0-methylglucose pretreated, STZ-injected group. *Significantly different 
from the nondiabetic group. 
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TABLE 7. Coronary flow rate (CFR) and coronary vascular resistance (CVR) of 
nondiabetic, diabetic and treated SHR. 
Group n 
Nondiabetic 12 
Diabetic 9 
T3-treated diabetic 9 
I-treated diabetic 14 
T3-treated control 7 
FR control 9 
OHG control 9 
CFR 
(cm3/sec) 
0.40 t 0.08 
0. 23 t 0.04* 
0.31 t 0.08 
0.41 t 0.07 
0.45 :t 0.08 
0.33 t 0.11 
0.38 :t 0.08 
CFR 
3 -1 (cm /sec . g ) 
0. 30 t 0.06 
0.26 t o.os 
0.34 t 0.09 
0.31 :t 0 .OS 
0.32 t 0.06 
0.31 t 0.10 
0.29 t 0.06 
CVR 
3 -1 -1 (kPa/cm . sec .g ) 
50.20 t 3.14 
49 . 22 t 3.26 
40.64 t 3.88 
45.26 t 3.36 
50.42 :t 4.70 
48.86 t 5. 56 
50.39 t 3.42 
CFR values are means t SD and CVR values are means :t SE, obtained 8 weeks after 
initiation of diabetes or treatment. CFR was measured when left atrial filling 
pressure was fixed at 15 cm H2o and resistance to aortic ejection was fixed at 
1 . 54 kPa/cm3 •min-1 • CVR is determined by plotting mean aortic pressure against 
coronary flow at the four resistances to aortic ejection, and obtaining the 
slope of the regression (see Methods). I-PZI and Lente insulin; T3, 
triiodothyronine; FR, food restricted nondiabetic group; OHG, 3-0-methylglucose 
pretreated, STZ-injected group. *Significantly different from the nondiabetic 
group. 
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Figure 1. (A) Systolic arterial pressure (SAP) and (B) heart rate 
(HR) in vivo, of nondiabetic (0), diabetic (e), insulin-treated 
diabetic (•) and triiodothyronine (T 3)-treated diabetic (•) SHR. The 
number of animals in each group is shown in parentheses. Values are 
means ±SD, obtained 8 weeks after initiation of diabetes or 
treatment. *Significantly different from the nondiabetic group. 
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1 
Figure 2. Cardiac performance ex vivo, as measured by (A) left 
ventricular pulse pressure (LVPP) or (Bl stroke work, of nondiabetic 
(0), diabetic (el, insulin-treated diabetic (~, and triiodothyronine 
(T 3J-treated diabetic ~) SHR. The hearts were volume loaded by 
varying left atrial filling pressure (LAFP) between 5 and 20 cm H2o. 
Resistance to left ventricular ejection was fixed at 1.54 
3 -1 kPa/cm .min . Values are means t SD, obtained 8 weeks after 
initiation of diabetes or treatment (n=7-12 per group). 
*Significantly different from the nondiabetic group. **Significantly 
different from the nondiabetic and diabetic groups. 
-46-
r 
)> 
.,, 
-0 
-n 
3 
::r: 
"b 
...__ 
0 
-
0 
r\) 
0 
0 
-0 
I\) 
0 
0 
0 
-
LVPP (KPa) 
I\) 
I\) (.71 
. • U1 0 
~ 
 
~ 
t-911>-4 ~ ••<? Q..0..0..::) 
\ " + + 0.. ~-· VJ . 
...... tMl-t 
*\ \ \ 
~ ~ 11>-i 
• 
-
SW (mJ/g) 
_!\) 
• 
I\) (11 
U'1 0 
OJ 
-47-
Figure 3. Cardiac performance ex vivo, as measured by (A) left 
ventricular pulse pressure (LVPP) or (B) stroke work, of nondiabetic 
(()), diabetic (el, insulin-treated diabetic (II), and triiodothyronine 
(T3 J-treated diabetic (•l SHR. The hearts were pressure loaded by 
varying resistance to aortic ejection between 0.19 and 3.13 
3 -1 kPa/cm .min . Left atrial filling pressure was fixed at 15 cm H2o. 
Values are means i SD, obtained 8 weeks after initiation of diabetes 
or treatment (n=7-12 per group). *Significantly different from the 
nondiabetic group. 
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Figure 4. Left ventricular pressure (LVP) waves from perfused 
working hearts of nondiabetic, diabetic, insulin-treated diabetic and 
triiodothyronine (T3)-treated diabetic SHR, under increasing 
pressure-loading conditions. Each of the four superimposed LVP waves 
was obtained at one of four resistances to aortic ejection: 0.19, 
3 -1 0.41, 1.54 and 3.13 kPa/cm .min . Left atrial filling pressure was 
fixed at 15 cm H2o. LVP waves were recorded from a single heart in 
each group and were obtained eight weeks after initiation of 
untreated or treated diabetes. Analog signals were digitized and 
stored on a diskette and regenerated using an IBM PC II with ASYST(R) 
software and an HP7470 plotter. Individual records were selected 
with the aim of approximating, as closely as possible, the mean 
maximum LVP values for each group as shown in Figure 3A. 
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SUMMARY 
Diabetes - and possibly the hypothyroidism which attends 
diabetes - impairs mechanical relaxation of ventricular muscle, in 
2+ part by depressing the rate of Ca uptake by sarcoplasmic reticulum. 
Left ventricular hypertrophy exacerbates the adverse effects of 
diabetes on cardiac performance but its effects on relaxation 
variables have not been well characterized. We examined the impact 
of streptozotocin-induced diabetes (8 weeks) on ventricular pressure 
load-dependent relaxation and sarcoplasmic reticular calcium uptake 
of hearts from spontaneously hypertensive rats and Wistar Kyoto rats. 
Subsets of diabetic hypertensive rats were treated with either 
insulin (10 U/kg/day) or triiodothyronine (8-10 µg/kg/day). Diabetes 
impaired load-dependent relaxation and depressed sarcoplasmic 
reticular calcium uptake only in spontaneously hypertensive rat 
hearts. Either insulin or triiodothyronine treatment prevented the 
diabetes-induced depressions of both mechanical and biochemical 
indices of relaxation. The results suggest that: 1) Hypertrophic 
ventricles of spontaneously hypertensive rats are more susceptible to 
the detrimental effects of diabetes on relaxation indices than are 
the nonhypertrophic Wistar Kyoto rat ventricles; and 2) The 
hypothyroidism which attends diabetes may contribute to the impaired 
relaxation of diabetic spontaneously hypertensive rat left ventricle. 
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INTRODUCTION 
Impaired mechanical relaxation is an important component of the 
1-3 
adverse effects of diabetes on cardiac performance Diastolic 
dysfunction involving prolonged relaxation is an early indication of 
clinical diabetic cardiomyopathy415 Characteristics of abnormal 
ventricular relaxation in diabetes include increased durations and 
reduced rates of decline in either the tension of isolated muscle 1 or 
the pressure of the intact ventricle 213 
One mechanism by which diabetes produces an impairment of 
ventricular muscle relaxation may involve the rate of calcium 
sequestration by the sarcoplasmic reticulum (SR). This biochemical 
measurement is assumed to be a determinant of mechanical relaxation6 . 
Diabetes often depresses SR calcium uptake, and the activity of the 
SR ca2+ -Mg2+ -ATPase, in rat ventricle7- 10 . 
Recent evidence suggests that left ventricular hypertrophy (LVH) 
. 1 11-13 
exacerbates functional defects of diabetic myocardium ' , 
including those which may have an impact on ventricular relaxation. 
The presence of LVH alone may or may not be associated with impaired 
relaxation14- 17 . However, when diabetes coexists with LVH in the 
spontaneously hypertensive rat (SHR), the rate of left ventricular 
pressure decline of perfused hearts is more profoundly depressed when 
d t th ff t f d . b t . t . t t . ll, 13 compare o e e ec s o ia e es in normo ens1ve ra s rains . 
Isometric relaxation is also prolonged in hypertrophic papillary 
muscles from the diabetic renovascular hypertensive rat12 These 
results would suggest that combined effects of diabetes and LVH on SR 
2+ Ca uptake might be more pronounced than the influence of either 
condition individually. However, the interaction between diabetes 
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and LVH on the relationship between myocardial relaxation and SR 
calcium uptake has not been characterized. 
Reduced serum levels of thyroid hormones are often associated 
with diabetes112112 , and this hypothyroidism (or "low thyroid state") 
may contribute to diabetic cardiomyopathy. Thyroid hormone 
deficiencies, like diabetes, can lead to prolonged relaxation and 
. 18 19 depressed rates of SR calcium uptake in the myocardium ' . The 
effects of hypothyroidism on these measurements are well correlated, 
both in nonhypertrophic and hypertrophic ventricles 20 . Treatment of 
the diabetic SHR with triiodothyronine (T3 ) effectively prevents the 
resultant cardiac dysfunction21 , but the influence of r 3 treatment in 
h t . d. b t . t d 1 . . . t t 22 - 24 non yper ens1ve ia e ic ra mo e s is incons1s en . 
Circumstantial evidence therefore provides a rationale for the 
following hypotheses: 1) The impairment in mechanical relaxation 
caused by diabetes can be correlated with the depression of SR ca 2+ 
uptake activity; 2) Both of these effects of diabetes are more 
pronounced on hypertrophic ventricles than they are on 
nonhypertrophic ventricles; and 3) Attendant hypothyroidism 
contributes to the effects of diabetes on mechanical and biochemical 
indices of ventricular relaxation in the SHR. The results of the 
study provide evidence in support of each hypothesis, demonstrating 
that T3 treatment can prevent both mechanical and biochemical defects 
in relaxation of the diabetic hypertrophic ventricle in the SHR 
model. 
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METHODS 
Animal Groups. Male SHR and Wistar Kyoto (WKY) rats were purchased 
from Charles River Breeding Labs (Wilmington, MA), then housed 
communally by strain and fed ad libitum. At 15 weeks of age, animals 
were weight matched and divided into either diabetic or nondiabetic 
groups. Diabetes was induced in lightly etherized animals by a 
single tail vein injection of streptozotocin (STZ; Sigma Chemical 
Co., St. Louis, MO). The dose of STZ for each strain was adjusted in 
order to induce similar degrees of diabetes as assessed by serum 
glucose concentrations. Based on preliminary results, equieffective 
doses of STZ in the WKY and SHR strains, as indexed by serum glucose 
elevations, were determined to be 50 mg STZ/kg BW and 45 mg STZ/kg BW 
respectively. The STZ was dissolved in citrate buffer (0.1 Hat pH 
4.5) just prior to use. The nondiabetic animals were also etherized 
and were injected with comparable volumes of the citrate buffer 
alone. Urinary glucose was detected in all animals of the diabetic 
groups (DIASTIX(R)). All animals were sacrificed eight weeks later. 
The diabetic SHR were divided into three subgroups corresponding 
to the treatment regimes initiated three days after STZ injection: 
1) protamine zinc insulin (I; Eli Lilly Co., Indianapolis, IN, 10 
U/kg/day sc); 2) T3 (Sigma, 8-10 µg/kg/day sc); and 3) untreated. We 
observed initially that treatment of diabetic SHR with 10 µg/kg/day 
of T3 was sufficient to just reverse the bradycardia in vivo. After 
6 weeks of T3 treatment, the dose was reduced to 8 µg/kg/day in order 
to avoid a progressive T3-induced tachycardia (see accompanying 
manuscript). The nondiabetic SHR were subdivided into two groups of 
untreated and T3-treated (8-10 µg/kg/day sc) animals. Treatment of 
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diabetic WKY with either insulin or T3 was unnecessary, because 
initial studies had shown that diabetes had little or no effect on 
mechanical indices of ventricular relaxation in this strain (see 
Results). 
In Vivo Measurements. Systolic arterial pressure (SAP), heart rate 
(HR) and body weight (BW) were taken just prior to the tail vein 
injections, and then four and eights weeks later. A standard 
tail-cuff sphygmomanometer within a temperature controlled chamber 
(34°C) was used to measure SAP and HR, after the animals were 
prewarmed for 10-15 minutes. All measurements were recorded prior to 
the daily injections of T3 or insulin. 
Serum Assays. Eight weeks after they were injected with STZ or 
citrate buffer, the animals were rapidly decapitated, and their serum 
was collected and stored at -20°c. The rats received the final 
injection on the day prior to sacrifice. The degree of diabetes was 
evaluated by serum glucose concentration using a glucose oxidase 
assay (Sigma). Animals were classified as diabetic if serum glucose 
values exceeded 300 mg/dL. Radioimmunoassays were used to determine 
serum insulin (Micromedic Systems Inc., Horsham, PA) and total T3 and 
thyroxine (T 4l concentrations (Cambridge Medical Diagnostics, 
Billerica, MA). Rat insulin was generously supplied by Dr. R. Chance 
(Eli Lilly) and was used as the standard for the insulin assays. 
Heart Perfusion. A subset of each animal group was used to assay 
left ventricular (LV) relaxation of isolated perfused working hearts. 
The hearts were quickly excised and perfused as described 
previously11 In brief, the perfusion apparatus was designed to 
manipulate LV pressure loads by altering resistance to aortic 
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ejection (see below). Left ventricular pressure (LVP) was 
continually monitored through an intraventricular cannula coupled to 
a pulse transducer (Statham, Hato Rey, PR). The aorta was tied to a 
14 gauge cannula and the heart was first perfused in a retrograde 
fashion for 3-5 min, then in the working mode for the remainder of 
the experiment. 
The hearts were perfused (nonrecirculating) with Krebs-Henseleit 
buffer maintained at 37°c. The buffer composition was 120 mH NaCl, 
5.6 mH KCl, 0.65 mH HgS0 4, 1.21 mH NaH 2Po 4, 25 mH NaHC0 3, 2.4 mH 
cac1 2, 0.2 mH EDTA and 10 mH glucose (pH 7.4 when warmed and gassed 
with 95\ o2 and 5\ co2 J. Hearts were paced at 300 beats per minute 
with a bipolar stimulating electrode placed on the right atrium. 
Prior to data collection, LVP was monitored in the working heart 
continually for 10-15 minutes on a Narcotrace Model 80 chart recorder 
(Narco Biosystems, Houston, TX) interfaced with a dedicated digital 
computer (Buxco Corp., Sharon, CT) to ensure stability to each 
preparation. During this time, left atrial filling pressure (LAFP) 
was fixed at 15 cm H2o and resistance to aortic ejection was set at 
3 -1 1.54 kPa/cm •min . Aortic flow could be directed through one of 
four segments of PE tubing, the length and diameter of which was 
varied in order to impose a final resistance of either 0.19, 0.41, 
1.54 or 3.13 kPa/cm3•min-l (calibrated at constant flow). 
Quantification of Left Ventricular Relaxation. Samples of the LVP 
waves were taken during pressure loading at the four aortic 
resistances and at constant LAFP (15 cm H20J. LVP waves were 
recorded and stored in an IBM PC II. Data acquisition was 
accomplished, in part, with the aid of A/D conversion hardware (Data 
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Translation, Marlborough, MA) and ASYST(R) software (Macmillan 
Software Co., New York, NY). At each pressure load, a series of five 
sequential LVP waves was recorded using an external trigger signal to 
initiate the data acquisition. Measurements obtiined from the 
digitized left ventricular waveforms (see Figure 1) included maximum 
left ventricular pulse pressure (P ), the time from the onset of 
max 
LVP rise at end-diastole to Pmax (Tp)' the time from Pmax to minimum 
diastolic LVP (T ), and the maximum rate of LVP decline (LV-dP/dt). 
r 
Maxima and minima of the LVP wave were obtained at the time points 
corresponding to zero value of the first derivative. The area under 
the LVP wave over T (A ) was used to quantify pressure 
r r 
load-dependent relaxation16 . For each heart and at each pressure 
load, P was plotted against Ar; the slope of the regression line 
max 
through the four points was used as the relaxation index (P /A). 
max r 
Preliminary studies showed that sampling and averaging of successive 
pressure waves was unnecessary because the variability between waves 
never exceeded 0.1\. The resolution of the digitized and stored 
waveform was 1 msec, each point representing the average of 400 2.5 
µsec samples. 
The hearts were removed from the perfusion apparatus and blotted 
dry after the data collection. The aorta and excess connective 
tissue were trimmed away and the following wet weights were obtained: 
whole heart (HW): left ventricular (LV) including the septum, and 
right ventricular (RV). These heart weights were used to assess the 
degree of ventricular hypertrophy. 
SR Calcium Uptake. Microsomes were prepared from left ventricular 
tissue of subgroups within each experimental group. Membrane 
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fractions enriched with SR were isolated either from single left 
ventricles or from pools of two left ventricles, as determined by 
preliminary studies of SR protein yield, by the method of Penpargkul 
et al. 9 with minor modifications. The need for pooling explains the 
differences in total sample size between groups in, for example, 
Tables 1 and 5. The hearts were removed, quickly trimmed, weighed 
and homogenized in 12 mL of a medium containing 0.3 M sucrose and 10 
mM imidazole (pH 7.4). The homogenate was centrifuged for 15 minutes 
at 2,000 x g. The supernatant was then centrifuged at 8,700 x g for 
another 15 minutes. The second supernatant was centrifuged a third 
time at 50,000 x g for 30 min. The pellet was resuspended in 10 rnL 
of 0.6 M KCl and 10 mM imidazole (pH 6.8), and centrifuged at 50,000 
x g for 30 minutes. The final pellet was resuspended in 2-3 rnL of 50 
mM KCl and 10 mM imidazole to yield a final concentration of 
approximately 100 µg/100 µL 9 . 
Calcium uptake was determined by using the Millipore filtration 
technique. Cardiac microsomes were characterized in the presence and 
absence of sodium azide, KCl, ATP and oxalate. Microsomes were 
pre-incubated for 3 min in 1 mL final volume, containing 5 mM ATP, 
120 mM KCl, 40 mM histidine HCl, 5 mM oxalate, 5 mM sodium azide, and 
5 mM HgC1 2 (pH 6.8 at 37°CJ. The reaction was initiated by adding a 
45 
solution containing EGTA, Ca and nonradioactive Cac1 2. The final 
concentration of EGTA was constant at 100 µH. Free calcium 
concentrations were calculated to range between 0.18 and 5.62 µH 25 . 
The reaction was terminated by filtering over 0.45 micron Millipore 
filters and washed with 2 mL Tris-HCl (20 mM). Filters were dried, 
counted in a liquid scintillation counter in 5 mL scintillation fluid 
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(BetaBlend(R), ICN Radiochemicals, Irvine, CA). Protein 
26 
concentrations were determined by the method of Lowry et al. . 
Rates of SR calcium uptake were expressed as µmoles/mg protein • 
min- 1 . Blanks consisted of microsomal preparations in the absence of 
added ATP. 
Statistical Analyses. The effects of diabetes and the hormone 
treatments of SHR were evaluated by one- or two-factor analysis of 
variance (ANOVA) with repeated measures when appropriate (Statistical 
Analysis Systems, Cary, NC). Comparisons between rat strains were 
made using two- or three-factor designs, with repeated measures when 
appropriate. Significance was set at the 0.05 level. Simple effects 
and Student Newman-Keuls multiple comparisons tests were used to 
evaluate significance. The mean square error term(s) from the parent 
ANOVA were used to calculate all follow-up statistics. 
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RESULTS 
Serum Assays. The injections of STZ induced a degree of diabetes, as 
quantified by serum glucose and insulin levels, which was equivalent 
in the SHR and WKY rat strains (Table 1). The diabetic animals were 
characterized by depressed serum T3 and T4 levels. The magnitudes of 
the depressions in thyroid hormone concentrations were about the same 
in the two strains, although both T3 and T4 levels of nondiabetic SHR 
were slightly higher than those of the nondiabetic WKY. 
Treatment of diabetic SHR with T3 prevented the decline in serum 
T3 levels, but had no effect on the elevated serum glucose or 
depressed insulin values (Table 1). It also exacerbated the decline 
in serum T4, probably by inhibiting TSH production and glandular T4 
secretion. T3 treatment of nondiabetic SHR had the same effect on T4 
levels, but otherwise did not alter glucose, insulin or T3 values. 
Treatment of diabetic SHR with insulin did not correct the 
hyperglycemia, at least at the 15-20 hour time point, even though it 
caused a pronounced increase in immunoreactive insulin activity 
(Table 1). This pattern may be evidence for subsensitivity to 
exogenous insulin in diabetic SHR. Insulin treatment was only 
partially effective in restoring serum T3 and T4 to normal. 
Body and Heart Weights. As expected, nondiabetic SHR had lower BW, 
but higher ratios of LV weight to either BW or (RV weight), than did 
nondiabetic WKY (Table 2). Thus, the left ventricles of SHR were 
both relatively (LV/BW) and absolutely (LV/RV) hypertrophic11 
Diabetes reduced BW and HW of SHR and WKY rats, and reduced LV/RV of 
SHR without affecting LV/BW. This indicates that diabetes had no 
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effect on relative hypertrophy, but reversed absolute hypertrophy of 
SHR left ventricles 11 . 
Treatment of diabetic SHR with T3 caused a further decline in 
BW, but had no effect on HW, thus it increased LV/BW (Table 2). 
However, T3 had no effect on LV/RV, and therefore did not affect the 
reversal of hypertrophy induced by diabetes. Treatment of 
nondiabetic SHR with T3 had no effect on any of the body or heart 
weight measurements. 
Insulin treatment (Table 2) nearly restored BW to normal, and 
prevented the declines in HW and LV/BW in diabetic SHR, in spite of 
its failure to correct the hyperglycemia1 
Arterial Pressure and Heart Rate In Vivo. As expected, nondiabetic 
SHR were hypertensive and tachycardic compared to the WKY animals 
(Table 3). The diabetic SHR were characterized by depressed SAP and 
HR ft 8 k f . . . b t . 11 a er wee s, con irming previous o serva ions However, 
diabetes had no effect on these measurements in the WKY strain. 
Treatment of diabetic SHR with T3, at a dose which was adjusted 
to prevent the bradycardia, only partially reversed the depressor 
effect of diabetes (Table 3). In contrast, insulin treatment 
prevented the decline in SAP but did not fully restore HR to normal. 
Treatment of nondiabetic SHR with T3 had no significant effect on 
either SAP or HR. 
Left Ventricular Pressure Wave Characteristics. Perfused hearts from 
nondiabetic SHR had a shorter Tr but otherwise did not differ from 
those of the WKY strain with regard to P , T , and LV -dP/dt (Table 
max p 
4). Diabetes increased Tp of both SHR and WKY hearts, but increased 
Tr and reduced Pmax and LV-dP/dt only in the SHR. None of these 
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changes was associated with differences in coronary flow or 
resistance, either within or between strains, confirming previous 
observations11120 (data not shown). 
All of the effects of diabetes on left ventr'icular pressure wave 
characteristics in the SHR strain were prevented by either T3 or 
insulin treatment (Table 4). However, none of these measurements was 
altered by T3 treatment of nondiabetic SHR. The effects of diabetes 
and treatment with either insulin or T3 on LVP waveforms are 
illustrated in Figure 1. 
2+ Pressure Load-Dependent Relaxation and SR Ca Uptake. Pressure 
load-dependent relaxation of SHR ventricles was impaired by diabetes, 
but that of the WKY hearts was not affected (Table 5, Figure 2). The 
rate of left ventricular SR calcium uptake was also depressed by 
diabetes only in the SHR (Table 5, Figure 3), so that the effects of 
diabetes on the two variables were well correlated between 
experimental groups. Both the mechanical and biochemical defects of 
diabetic SHR ventricle were reversed by either insulin or T3 
treatment (Table 5, Figures 1-3). Therefore, T3 treatment was as 
effective as insulin therapy in preventing the impairment in 
mechanical relaxation, and the depressed SR calcium uptake activity, 
of diabetic SHR ventricle. Treatment of nondiabetic SHR with T3 had 
no significant effect on either the relaxation index (Table 5, Figure 
2) or the rate of SR calcium uptake (Figure 3). 
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DISCUSSION 
A common biochemical defect of diabetic myocardium is a 
depressed rate of calcium sequestration by SR microsomes 7 . Proposed 
mechanisms include reductions in either the density or the activity 
of ca2+-Hg2+ ATPase819118 , alterations in membrane lipid 
profiles8127128 , and changes in the degree of membrane 
phosphorylation29 Until now, studies of this kind have been 
restricted to nonhypertensive, nonhypertrophic models. Our data 
suggest, however, that the adverse effect of diabetes on left 
ventricular SR calcium uptake activity is exacerbated by preexisting 
LVH (Figure 3, Table 5). Thus, diabetes of equal duration and 
severity - as measured by serum glucose and insulin levels -
2+ depressed SR Ca uptake of SHR left ventricles, but had no effect in 
the nonhypertensive, nonhypertrophic WKY strain. These results 
extend those of earlier studies which had demonstrated that the 
detrimental effects of chronic diabetes on various indices of cardiac 
mechanical activity are more pronounced on hypertrophic than on 
nonhypertrophic ventricles of both SHR and renovascular hypertensive 
t 11-13 ra s . (See accompanying manuscript.) 
The mechanism for the apparent interaction between diabetes and 
2+ LVH on SR Ca uptake is a matter of speculation. In nondiabetic 
h t h . t . 1 SR C 2+ t k . ht b . . d2o, 3o yper rop ic ven r1c e, a up a e m1g e impa1re or 
31 
normal , depending perhaps on either the experimental model or the 
duration of hypertension32 Like diabetes, LVH is associated with 
alterations in lipid metabolism33134 and restricted fuel source 
·1 b"l"t 35,36 ava1 a i i y Elevated workloads, 
and possibly increased metabolic demand 
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37 
reduced coronary reserve 
for carnitine 33 (see below) 
may combine to predispose the hypertrophic ventricle to 
membrane-disrupting effects of diabetes which might otherwise be less 
apparent in the absence of preexisting LVH. 
Our results also show that the activity of SR ca 2+ uptake was 
well correlated with indices of mechanical relaxation. Both 
measurements were depressed in the diabetic SHR, but neither one was 
significantly affected in any other experimental group (Table 5, 
Figure 3). Cardiac muscle relaxation can be categorized as 
consisting of inactivation-dependent and afterload-dependent 
mechanisms; the latter is considered to be more closely linked to 
intracellular calcium sequestering mechanisms 38 Load-dependent 
relaxation is most often demonstrated in isolated ventricular muscle 
preparations. A recent report from this laboratory suggested that 
the ratio Pmax/Ar can serve as an index of load-dependent relaxation 
in the ejecting ventricle 16 . As expected, the value of P /A in 
max r 
2+ the present study correlated with the rate of SR Ca uptake between 
experimental groups (Table 5, Figures 2 and 3). The T variable did 
r 
not correlate as well, because it differed between nondiabetic SHR 
and WKY groups, whereas the SR ca 2+ uptake activity did not (Tables 4 
d 5) I t t t th lt f th . t 16 . th" an . n con ras o e resu s o e previous repor , in is 
study LV -dP/dt varied with P /A . However, the former variable is 
max r 
inconsistent and difficult to interpret, largely because of its 
dependence on the configuration of the pressure wave. Overall, our 
results strongly suggest that diabetes impairs load-dependent 
relaxation of hypertrophic ventricle, although diabetes likely 
compromises inactivation-dependent relaxation mechanisms as 
111,12,38 we . Whether or not diabetes can specifically depress 
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load-dependent relaxation of nonhypertrophic myocardium remains to be 
determined. 
The effectiveness of T3 treatment to completely prevent the 
diabetes-
induced impairments in relaxation and SR ca 2+ uptake of SAR ventricle 
(Tables 4 and 5, Figures 2 and 3) was somewhat surprising. In two 
previous reports, hypothyroidism induced in SHR by either 
methimazole 11 or thyroidectomy 20 only partially duplicated the 
effects of diabetes on mechanical function. In normotensive diabetic 
rats, insulin therapy can ameliorate impaired mechanical function 
without completely correcting the depressed serum thyroid hormone 
1 levels . The dose of T3 used in the current study, 8-10 µg/kg/day, 
was selected on the basis of its ability to restore the depressed HR 
in vivo of diabetic SHR to normal (see Table 3). This dose probably 
did not impose a hyperthyroid state in the diabetic SHR for several 
reasons: 1) It did not significantly increase serum T3 levels above 
those of the nondiabetic controls, although it apparently did inhibit 
T4 production by the thyroid gland (Table l); 2) The same dose given 
to the nondiabetic SHR had no effect on heart or body weights, or on 
SAP or HR in vivo (Tables 2 and 3); 3) T3 treatment of nondiabetic 
SHR also had no significant effect on either serum T3 levels (Table 
1), indices of mechanical relaxation, or the rate of SR ca 2+ uptake 
in vitro (Tables 4 and 5). Earlier studies had indicated that 
"physiological doses" of thyroid hormone - i.e., those which had been 
shown to be sufficient for replacement therapy of simple 
hypothyroidism - were only partially effective in restoring cardiac 
function of diabetic normotensive rats 8122123124 . Interestingly, 
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however, T3 (10 µg/kg, twice/day) given for only the final 5 days of 
a 2-week period of diabetes, almost completely reversed the prolonged 
action potential duration in diabetic Wistar rat atria 39 . 
Our results suggest that hypertension, and probably left 
ventricular hypertrophy, increase the responsiveness of diabetic 
myocardium to the ameliorative effects of T3 therapy, at least with 
regard to mechanical and biochemical indices of relaxation. The 
mechanism may involve, in part, differential effects of diabetes on 
membrane lipid profiles, and other aspects of lipid metabolism, of 
hypertrophic vs. nonhypertrophic ventricle. The acute effects of T3 
on ca2+-Hg2+-ATPases are profoundly influenced by the lipid 
environment40 . Because hypertrophy41 , hypothyroidism40 and 
diabetes 42 all affect membrane lipid composition, it seems reasonable 
to hypothesize that different combinations of these pathophysiologic 
conditions would have variable influences on the subsequent effects 
of T3 administration. In normotensive rats, myoinositol 
coadministration increases the therapeutic efficacy of T3 in diabetic 
cardiomyopathy43 Fatty acyl esters of carnitine may be especially 
important. Enhanced incorporation of long chain acyl carnitines 
(LCAC) into the SR membrane is correlated with depressed rates of 
calcium uptake in diabetes27 and T3 treatment decreases LCAC levels 
in SR membranes 44 . Another potential mechanism undoubtedly involves 
the regulation of SR calcium pump activity by thyroid hormone. 
Chronically, T3 probably increases the rate of SR ca
2+ uptake by 
accelerating the synthesis of ca 2+-Hg 2+-ATPase enzyme molecules, and 
hypothyroidism has opposite effects on these rneasurements 45 . The 
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data from our study (Figure 3) and those of a previous report 16 are 
consistent with such an effect of thyroid state in diabetic SHR. 
In summary, the results of this study show that the interaction 
between diabetes and LV hypertrophy is manifested· by defects in 
biochemical and mechanical measurements of ventricular muscle 
relaxation. They also demonstrate that this condition is completely 
preventable by treatment of diabetic SHR with T3. The possibility 
that these two consequences of hypertensive hypertrophy in the SHR 
model - exacerbation of diabetic cardiomyopathy and predisposition to 
the ameliorative effects of T3 treatment - might be mechanistically 
interrelated remains to be investigated. 
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TABLE 1. Serum glucose, insulin, T3 and T4 values of nondiabetic and diabetic 
SHR and WKY rats. 
Group n Glucose 
(mq/dLl 
~ 
Nondiabetic 20 124 + 20 
* Diabetic 18 580 + 65 
t 
Diabetic + T3 18 615 ± 77 
t 
Diabetic + I 16 542 + 196 
Nondiabetic + T3 15 132 ± 27 
m 
Nondiabetic 21 149 ±. 34 
* Diabetic 16 567 ±. 118 
Insulin 
(µU/mLl 
68 
.i 26 
* 16 ±. 6 
t 
25 + 14 
** 287 ± 165 
69 + 15 
77 ±. 21 
* 22 + 9 
T3 
(ng/dLl 
99 ±. 19y 
* 47 ±. 13 
118 .i 64 
** 71 .i 23 
109 ±. 50 
86 ±. 13 
* 41 ±. 11 
5.52 ±. 1.93 
2.12 ±. 0.76 
0.21 + 0.12 
4.12 + 1. 60 
0.27 ±. 0.15 
4. 62 ±. 1.12 
2.60 ±. 0.68 
Values represent means ±. SD, obtained 8 weeks after initiation of diabetes or 
treatment. T3, triiodothyronine; I, protamine zinc insulin. 
* Significantly different from the nondiabetic group (within strain). 
** Significantly different from the nondiabetic and diabetic groups (within 
strain). 
Y Significantly different from the nondiabetic WKY. 
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* 
tt 
•• 
** 
* 
TABLE 2. Body and heart weights of nondiabetic and diabetic SHR and WKY rats. 
Group n BW HW LV/BW LV/RV 
(g) (mg) (mg/g) (mg/mg) 
m 
Nondiabetic 20 328 .t 25y 1370 .t 132 3.20 .t 0. 40 y 5.37 i0.72y 
t 
* 
t 
Diabetic 18 196 ±. 21 907 + 85 3.04 ±. 0.51 4.42 ±. 1.04 
tt t t t 
Diabetic + T3 18 174 .t 21 929 .t 146 3.68 i 0.63 4.41 .t 0.73 
tt 
Diabetic + I 16 305 ±. 25 1371 ±. 83 3.00 ±. 0. 59 4.84 ±. 1.11 
Nond iabe tic + T 3 15 322 ±. 35 1406 ±. 75 3.36 ±. 0.58 4.86 ±.0.90 
m 
Nondiabetic 21 386 ±. 31 1428 ±. 182 2.66 ±. 0.37 4.31 ±. 0.80 
t 
* Diabetic 16 306 ±. 37 1070 + 75 2.75 ±. 0.50 4.13 ±. 0.66 
Values represent means ±. SD, obtained 8 weeks after initiation of diabetes or 
treatment. BW, body weight; HW, heart weight; LV, left ventricular weight; RV, 
right ventricular weight; T3, triiodothyronine; I, protaaine zinc insulin. 
* Significantly different from the nondiabetic group (within strain}. 
tt Significantly different from the nondiabetic and diabetic groups (within 
strain}. 
Y Significantly different from the nondiabetic WKY. 
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TABLE 3. Systolic arterial pressure and heart rates of nondiabetic and 
diabetic SHR and WKY rats. 
Group n SAP (kPal HR (beats/min) 
Week 0 Week 8 Week 0 Week 8 
~ 
Nondiabetic 20 23.6 ± 3.21 26.4 .! 24 l 386 .! 401 422 .! 461 
* * Diabetic 18 23.7 ±. 2. 8 20.0 ±. l. 9 377 ±. 33 287 t 29 
** Diabetic + T3 18 24.4 ± 2.0 23.6 .±. 3.2 390 .±. 40 439 .±. 50 
** Diabetic + I 16 23.5 ± 2.0 26.9 .±. 2.7 384 .±. 28 389 .! 36 
Nondiabetic + T3 15 23.7 .±. 1.6 28.2 .±. 3.1 400 .±. 29 456 .±. 57 
m 
Nondiabetic 21 17.1±.1.7 18.8 ±. 1. 5 315 ±. 49 302 ±. 29 
Diabetic 16 17.3 ±. 1. 7 17.9 ±. 2.3 311 !. 19 275 !. 22 
Values represent means ±. SD, obtained 8 veeks after initiation of diabetes or 
treatment. SAP, systolic arterial pressure; HR, heart rate; r3, 
triiodothyronine; I, protamine zinc insulin. 
* Significantly different from the nondiabetic group (within strain). 
** Significantly different from the nondiabetic and diabetic groups (within 
strain). 
1 Significantly different from the nondiabetic WKY. 
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TABLE 4. Left ventricular pressure wave characteristics of nondiabetic and 
diabetic SHR and WKY rat hearts ~ Y1:l2_. 
Group n 
~ 
Nondiabetic 12 
Diabetic 9 
Diabetic + T3 9 
Diabetic + I 7 
Nondiabetic + T3 7 
m 
Nondiabetic 13 
Diabetic 9 
P max 
(kPa) 
19.1 ± 0.9 
14.7 ±. 1. 9 
17.9 ±. 0. 7 
20.0 ±. 1.5 
20.9 + 1.6 
18.9 ±. 2.7 
17.l ±. 2. 0 
* 
38 ± 3 
t 
42 ±. 6 
34 ±. 5 
41 ±. 3 
34 + 6 
36 ±. 4 
t 
45 ±. 5 
Tr 
(msec) 
83 ± 
104 + 
82 ±. 
80 ±. 
78 + 
99 ±. 
51' 
* 8 
8 
6 
5 
9 
98 ±. 12 
LV-dP/dt 
(kPa/sec) 
600 + 92 
416 ±. 113 
549 + 76 
601 ±. 70 
645 ± 105 
541 ±. 134 
517 ±. 108 
Values represent means ±. SD, obtained 8 weeks after initiation of diabetes or 
t 
treatment. Pmax' maximum left ventricular developed pressure (LVDPl; Tp' time 
to Pmax; Tr' time from Paax to minimum LVDP; LV-dP/dt, maximum rate of left 
ventricular pressure decline; T3, triiodothyronine; I, protamine zinc insulin. 
Left ventricular filling pressure was fixed at 15 cm H2o and resistance to 
aortic ejection was fixed at 1.54 kPa/cm3.min-l. 
t Significantly different from the nondiabetic group (within strain). 
1
significantly different from the nondiabetic WKY. 
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TABLE 5. 2+ Ventricular relaxation index and SR ca uptake of nondiabetic and 
diabetic SHR and WKY rats. 
Group 
m 
Nondiabetic 
Diabetic 
Diabetic + T3 
Diabetic + Insulin 
Nondiabetic + T3 
m 
Nondiabetic 
Diabetic 
s 
n 
12 
9 
9 
7 
7 
13 
9 
Relaxation Index 
-1 (sec ) 
16.7 ±. 0.6 
12.6 i 1.1 
18.8 i 0.7 
18.1 ±. 0.8 
17.2 .±. 0.6 
15.4 ±. 0.9 
13.3 ±. 1.0 
* 
++ SR ca Uptake 
(nmoles/mq.min-l) 
6 42.3 ±. 7.4 
* 4 14.2 i 1.4 
4 45.7 i 6.0 
4 49.0 ±. 3.8 
4 59.6 + 4.5 
6 53.4 ±. 3.0 
4 47.4 ±. 8.3 
Values represent means ±. SE, obtained 8 weeks after initiation of diabetes or 
treatment. Microsomal ca 2+ uptake was stimulated by io-5· 5 H free calcium (see 
· Figure 2). T3, triiodothyronine; I, protamine zinc insulin. 
1Number of individual perfused hearts . 
+Number of groups of pooled left ventricles . 
• Significantly different from the nondiabetic SHR group. 
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Figure 1. Computer print-out of left ventricular pressure (LVP) 
waves from nondiabetic (nd), diabetic (d), insulin-treated diabetic 
(d+i) and T3 treated diabetic (d+t 3) SHR hearts ex vivo. Each LVP 
wave was recorded from a single heart at a fixed pressure load 
3 -1 (resistance to aortic ejection) of 3. 13 kPa/cm .min , and volume 
load of 15 cm H2o. The LVP waves were chosen in order to closely 
represent the mean values of contraction and relaxation indices for 
each experimental group. The indices used to assess mechanical 
function are depicted on the nondiabetic SHR LVP wave (left) and 
include: maximum LVP (Pmax); time to Pmax (T ); total time of p 
pressure decline (Tr); and area under the LVP wave during Tr (Ar). 
For further details, see Methods. 
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Figure 2. Pressure load-dependent relaxation of nondiabetic (O), 
diabetic (el, insulin-treated diabetic (•), T3-treated diabetic (~), 
and T3-treated nondiabetic (~) SHR hearts ex vivo. The four points 
within each group represent maximum left ventricular pulse pressure 
(Pmax) vs. the area under the falling phase of the pressure wave (Ar) 
at each of four pressure loads (see Figure 1). Loading was altered 
stepwise by fixing the resistance to aortic ejection at 0.19, 0.41, 
3 -1 1.54, or 3.13 kPa/cm .min (see Methods). The slope of the 
regression line through the four points within each group is the 
value of the relaxation index (see Table 5). Only the untreated 
diabetic group was characterized by a significantly depressed 
relaxation index. Therefore, for simplicity, a single line 
representing the collective mean slope is depicted for the remaining 
experimental groups. Values represent means (n = 7-12), obtained 8 
weeks after initiation of untreated and treated diabetes. 
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1.0 1.2 
Figure 3. Rate of sarcoplasmic reticular (SR) calcium uptake of left 
ventricular microsomes from nondiabetic (0), diabetic (el, 
insulin-treated diabetic (Im), T3-treated diabetic (•l and T3-treated 
nondiabetic ~) SHR (left), and nondiabetic (0) and diabetic (I) WKY 
(right). Values represent means i SE, obtained 8 weeks after 
initiation of diabetes or treatment (n = 4-6 pooled samples). 
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Ventricular Action Potentials in Diabetic SHR: 
Alterations prevented by Insulin or T3 
-88-
ABSTRACT 
Diabetes imposes a pronounced cardiodepression in the 
spontaneously hypertensive rat (SHR), which may be attributable, at 
least in part, to attendant hypothyroidism. A prolongation of the 
ventricular action potential duration (APO) characteristic of either 
diabetes or hypothyroidism, may be associated with this impairment. 
Thyroid hormone treatment (in vivo) prevents mechanical and 
biochemical deficits in hearts from diabetic SHR. Chronic diabetes 
(8 weeks) was chemically-induced in SHR and normotensive Wistar Kyoto 
(WKY) rats by a single tail vein injection of streptozotocin (STZ; 45 
mg/kg and 50 mg/kg, respectively). A subgroup of diabetic SHR were 
treated with daily injections of either insulin (10 U/kg/day) or 
triiodothyronine (T 3; 8-10 µg/kg/day). Systolic arterial pressure 
(SAP) and heart rate (HR) were recorded in vivo, before and 8 weeks 
after STZ injections. As expected, diabet~s reduced SAP in SHR and 
lowered HR in both the SHR and WKY rats. Either insulin or T3 
treatment of diabetic SHR prevented the drop in SAP and HR. Absolute 
left ventricular hypertrophy as assessed by the ratio of left to 
right ventricular weights, was reversed by diabetes in SHR. The 
reversal was partially prevented by insulin, but not by T3, 
treatment. Diabetes prolonged APO to the same extent in SHR 
ventricular muscle as it did in WKY muscle, and these effects were 
independent of changes in resting membrane potential, action 
potential amplitude or rate of rise of the upstroke (Vmax). 
Hypertrophy alone had no effect on APO, since this measurement was 
the same in both nondiabetic SHR and nondiabetic WKY rats. Thyroid 
hormone treatment was as effective as insulin was in preventing the 
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diabetes-induced changes of APO in SHR papillary muscle. These data 
suggest that prolongation of APO of ventricular muscle caused by 
chronic, untreated diabetes is not affected by left ventricular 
hypertrophy. Furthermore, the data provide additional support that 
the attending hypothyroidism is functionally significant in the 
diabetic cardiomyopathy of SHR. 
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INTRODUCTION 
Hypertrophy may predispose the myocardium to the adverse effects 
of diabetes. Both clinical and experimental evidence indicate that 
cardiomyopathies are more severe and perhaps more ' frequent when these 
pathological conditions coexist (7, 15, 30). Experimental studies 
further show that mechanical, biochemical and morphological indices 
of cardiac function are more severely impaired in diabetic 
hypertensive rats than in animals with either disease alone (11, 12, 
16, 18, 42, 57). 
A hypothyroid state is often associated with poorly controlled 
diabetes (40). In addition to low serum thyroid hormone levels, 
diabetes impairs peripheral T4 to T3 conversion, tissue T3 uptake, 
and both affinity and density of nuclear T3 receptors (5, 8). The 
influences of attendant hypothyroidism on the cardiovascular system 
may be difficult to distinguish from those of diabetes. Indeed, 
certain cardiovascular manifestations of experimental diabetes, such 
as the bradycardia, may be entirely attributable to the impaired 
thyroid state (54). The effectiveness of thyroid hormone treatment 
on the progression of diabetic cardiomyopathies are not consistent 
(22, 53) but may be more apparent in the presence of left ventricular 
hypertrophy (11, 12). Recently we have shown that the functional 
impairments in diabetic spontaneously hypertensive rat (SHR) hearts 
can be prevented by treating animals with either insulin or 
triiodothyronine (T 3; 11). Treatment of SHR with T3 also prevented 
the diabetes-induced depressions of sarcoplasmic reticular (SR) 
calcium uptake and its mechanical correlate, ventricular relaxation 
( 12). 
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The relationship between the electrical properties of the 
sarcolemrna and contractile events of cardiac muscle is well 
characterized (for reviews see 19 and 36). The cardiac action 
potential (AP) configuration is similarly altered by the effects of 
either hypertrophy, diabetes, or hypothyroidism (4, 9, 10, 17, 37, 
47). Prolongation of the cardiac AP is the most consistent 
consequence common to all three abnormalities, and may be 
functionally related to associated mechanical alterations which are 
also characteristic of each condition. A combination of these 
disease states may have additive effects on ventricular transmembrane 
potentials (18), as they seem to have on mechanical function (11, 
12). 
The central purpose of this study was to characterize the 
influence of chronic, untreated diabetes on the configuration of the 
papillary muscle AP in SHR and normotensive WKY rats. Additional 
aims included the assessment of the effectiveness of T3 treatment, 
compared to that of insulin therapy, on ventricular electrophysiology 
in diabetic SHR. The results show that diabetes prolongs the cardiac 
AP to the same extent in hypertrophic and nonhypertrophic papillary 
muscle. Furthermore, T3 treatment is as effective as insulin in 
preventing the diabetes-induced AP prolongation. 
-92-
METHODS 
Animal Groups. Male spontaneously hypertensive rats (SHR) and Wistar 
Kyoto (WKY) rats were purchased from Charles River Breeding 
Laboratories (Wilmington, MA), then housed communally according to 
strain, and fed ad libitum. When the animals were 15 weeks of age, 
they were weight matched and assigned to either nondiabetic or 
diabetic groups. Diabetes was induced by a single tail vein 
injection of streptozotocin (STZ; Sigma Chemical Co., St. Louis, MO) 
in lightly etherized animals. The dose of STZ was adjusted for each 
strain in order to induce comparable degrees of diabetes as indexed 
by serum glucose levels (12): SHR, received 45 mg/kg, and WKY 
received 50 mg/kg. The STZ was dissolved in citrate buffer (0.1 Mat 
pH 4.5) just prior to use. The nondiabetic animals were also 
etherized and given comparable volumes of citrate buffer alone. 
Glucose appeared in the urine (DIASTIX) of all STZ treated animals. 
All animals were sacrificed eight weeks after the tail vein 
injections. 
The diabetic SHR were divided into three subgroups corresponding 
to specific treatment regimes which were initiated three days after 
the STZ injection. One subgroup of diabetic SHR was treated with 
protamine zinc insulin (I; Eli Lilly Co., Indianapolis, IN), 10 
U/kg/day sc, administered once each day at 1600 hrs. The second 
subgroup of diabetic SHR was given a single daily injection of 
triiodothyronine (T3; Sigma) 8-10 ug/kg/day sc (also at 1600 hrs). 
After 6 weeks of treatment, the T3 dose was reduced from 10 ug/kg/day 
to 8 ug/kg/day in order to avoid the development of T3-induced 
tachycardia (11). This dose of T3 was selected according to its 
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ability to just prevent the progression of bradycardia during the 8 
week period of diabetes (11, 42). The third subgroup of diabetic SHR 
remained untreated for the entire 8 week period. 
In Vivo Measurements. Systolic arterial pressure (SAP), heart rate 
(HR) and body weight (BW) were measured prior to the STZ injections, 
and then eight weeks subsequently. SAP was monitored continually 
until three or more consistent measurements were observed, using a 
standard tail-cuff sphygmomanometer contained in a temperature 
controlled chamber (34°C). HR was also monitored with the tail-cuff 
apparatus, before and after the SAP recordings. These measurements 
were obtained prior to the daily T3 or insulin injections. 
Intracellular Recordings. Eight weeks following the tail vein 
injections, all animals were rapidly decapitated, the hearts were 
quickly excised and a papillary muscle was removed and prepared for 
intracellular recordings. A papillary muscle with an origin on the 
left ventricular outer wall was isolated and superfused with 
nonrecirculating Krebs-Henseleit buffer maintained at 34°c. The 
buffer composition was (mM); 120 NaCl, 5.6 KCl, 0.65 Mgso4, 1.21 
NaH 2Po 4, 25 NaHco 3, 2.4 CaC1 2, 0.2 EDTA and 10 glucose (pH 7.4 when 
warmed and gassed with 95% o2 and 5% co 2). In order to minimize the 
degree of contraction during electrical stimulation, muscles were 
loosely anchored to the base of the preparation chamber. The buffer 
capacity of the chamber was 8 ml and the flow rate through the 
chamber was maintained at approximately 3 ml/min. Each muscle 
preparation was allowed to equilibrate in buffer for 30 min prior to 
recording membrane potentials. A bipolar, silver wire suction 
electrode was used with a Grass SD9 stimulator (Grass Instruments, 
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Quincy, MA) to evoke cardiac action potentials at a frequency of 1 
Hz. Stimulus intensities were set just above threshold voltages with 
square wave pulses of 0.5 ms duration. The stimulating electrode was 
placed at the apical end of the muscle . Standard intracellular 
electrodes were filled with 3 M KCl and connected to a DC 
preamplifier (Model SVC 2000, WPI, New Haven, CT). Transmembrane 
potentials were monitored continuously on a storage oscilloscope 
(Model 5103N, Tektronix, Beaverton, OR), and simultaneously monitored 
and stored, for off-line analysis, in an IBM PCII, using A/D 
conversion hardware (Data Translation, Marlborough, MA) and ASYST 
software (Macmillan Software Co, New York, NY). The sampling rate of 
the A/D conversion was 1.25 µs, of which the digitized data were 
averaged, sampled and stored every 1 ms. Data acquisition was 
synchronized by externally triggering A/D conversion through the 
stimulator. For each muscle fiber sampled, 4-5 action potentials 
were recorded, and an average of 7 muscle fibers were sampled from 
each animal. 
AP Configuration Analysis. The resting membrane potential (RP) was 
recorded and the action potential (AP) configuration was described 
using the following indices; AP amplitude (AMP), time course to 
complete repolarization (AP duration at 10% (APDlO), 25\ (APD25), 50\ 
(APD50) and 75\ (APD75) repolarization). The maximum rate of rise of 
the depolarization (V ) was determined by calculating the maximum 
max 
first derivative of the stored AP. 
Heart Weight Ratios. Prior to the removal of the papillary muscle, 
the hearts were quickly blotted dry and the following wet weights 
were obtained; whole heart (HW), left ventricle (LV) including the 
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septum, and right ventricle (RV). The degree of ventricular 
hypertrophy was assessed using these heart weights. 
Statistical Analvses. The effects of diabetes on SAP and HR within 
and between each strain were assessed using a three-way analysis of 
variance (ANOVA) with repeated measures. These in vivo measurements 
were also assessed in diabetic SHR treated with either insulin or T3 
by means of a two-way ANOVA with repeated measures. To evaluate the 
treatment effects for all ex vivo measurements, similar statistical 
designs were employed, but without a repeated measures factor. The 
membrane potential data presented for each experimental group 
actually represent the average values from multiple samples within a 
given muscle fiber, and multiple fibers within a given papillary 
muscle. Thus, sample sizes presented in Table 3 reflect the number 
of animals within each experimental group, rather than the number of 
individual fibers sampled. Probability values of 0.05 or less were 
considered sufficient to indicate significant differences between 
group means. Simple effects and Student Newman-Keuls multiple 
comparisons tests were used to further evaluate significant F values. 
The mean square error term(s) from the parent ANOVA were used for the 
follow-up tests. 
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RESULTS 
Systolic Arterial Pressure and Heart Rate. At 15 weeks of age (week 
0 in Table 1), SHR were already hypertensive and tachycardic when 
compared to WKY. As previously reported, diabetes depressed systolic 
arterial pressure (SAP) in SHR but not in WKY (42). Either insulin 
or T3 treatment prevented the depressor effects of diabetes in the 
SHR. Similarly, heart rate (HR) was also reduced in diabetic SHR, 
and maintained at nondiabetic levels by either insulin or T3 
treatment. Diabetes did not produced a bradycardia in the WKY. 
Body and Heart Weights. Diabetes reduced body weight (BW) and whole 
heart weight (HW) in both the SHR and WKY strains (Table 2). Insulin 
treatment prevented this BW loss, but only partially prevented 
diabetes-induced HW loss. Treatment with T3 did not influence the BW 
or HW in diabetic SHR. Absolute left ventricular hypertrophy 
(LV/RV), but not relative ventricular hypertrophy (LV/BW) was 
apparent in the hypertensive SHR when compared to the normotensive 
WKY. Diabetes decreased LV/RV in SHR, without altering LV/BW. 
Insulin treatment, unlike T3 treatment, partially prevented the 
diabetes-induced reversal of LV/RV ratio in SHR. Diabetes had no 
effect on ventricular weight ratios in WKY. 
Cardiac Action Potentials. The membrane potentials of papillary 
muscles from nondiabetic SHR were quantitatively similar to those of 
nondiabetic WKY muscles (Figure 1, Table 3 and Table 4). There were 
no significant strain-dependent differences with regard to resting 
membrane potential (RP), action potential (AP) amplitude (AMP), and 
AP duration to 10% repolarization (APDlO), 25% repolarization 
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(APD25), 50\ repolarization (APD50) and 75\ repolarization (APD75), 
or V 
max 
Diabetes prolonged the APO to the same extent in both SHR and 
WKY papillary muscles (Figure 1, Table 3 and Table 4). This 
prolongation of the AP was observed at all points sampled after peak 
depolarization. Diabetes-induced changes in AP configuration were 
independent of changes in RP, AMP or V 
max 
Treating diabetic SHR with either insulin or T3 in vivo 
completely prevented the changes in AP configuration in vitro (Figure 
1 and Table 3). The RP, AMP and V of muscles from insulin-treated 
max 
and T3-treated diabetic SHR were the same as those from nondiabetic 
SHR. T3 treatment as well as insulin treatment completely prevented 
the diabetes-induced increases in APO at all stages of 
repolarization. 
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DISCUSSION 
The results of this study show that diabetes prolongs the 
cardiac action potential (AP) in SHR and in WKY papillary muscles, 
and that the AP duration (APO) of nondiabetic SHR and WKY rat muscle 
were not different (Table 3). The results provide additional 
evidence that the 23 week-old SHR is in the adaptive stage of 
hypertrophy (39), in which the ventricular muscle is electrically, 
mechanically (42) and, in part, biochemically (12) normal. Volkmann 
et al. (56) described similar results when comparing membrane 
potentials from 15 week-old SHR and WKY. Our data also show that the 
adverse effect of untreated diabetes on AP configuration in both 
hypertrophic and nonhypertrophic muscle are quantitatively similar. 
A prolonged APO is characteristic of diabetic, hypothyroid and 
compromised hypertrophic ventricular muscle (9, 10, 17, 27, 37). The 
cellular basis for the increased APO is not yet known. It has been 
suggested that the net inward current during the plateau phase is 
increased with hypothyroidism (20) or hypertrophy (33), perhaps due 
to a decrease in outward Kt current. An increased density of 
voltage-dependent calcium channels in hypothyroid rat hearts (26) 
could also explain these findings. Furthermore, the time course of 
the AP of hypertrophic muscle appears to be extended by a depressed 
rate of inactivation of the slow inward current, when compared to 
normal muscle cells (4, 33). It is still not clear whether the 
underlying mechanisms which prolong the AP in cardiac muscle of 
diabetic, hypertensive and hypothyroid animals have a common ionic 
basis. 
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The influx of calcium during the cardiac AP probably increases 
with extended depolarization times, regardless of the mechanism of 
APD prolongation. A number of investigators have linked depressed 
mechanical activity with increased intracellular calcium 
concentrations (1, 4, 37), since an excess of free intracellular 
calcium can be toxic to the cell (13). Whether calcium overload 
exists with diabetes is still a source of debate (13, 29, 48); 
nonetheless, abnormal intracellular calcium handling is a common 
phenomenon among diabetic, hypertrophic and hypothyroid cardiac 
tissue (21, 38, 43). 
Increased duration of the cardiac AP is often associated with 
disrupted mechanical activity in diabetic (17, 37) and hypertrophic 
myocardium (4, 10, 25, 28, 55). The results of this study are 
consistent with the pronounced mechanical deficits imposed by 
diabetes on the intact ventricle of SHR (11, 12, 42, 45, 57). 
Diabetes reduces maximum left ventricular (LV) pressure and rates of 
contraction and relaxation in the isolated working SHR heart (11, 
42). It also depresses a biochemical correlate of relaxation, the 
rate and extent of calcium uptake by the sarcoplasmic reticulum (SR) 
in SHR (12). Prolongation of the AP is also evident of renovascular 
hypertensive (RVH) rat in papillary muscle (3) and is exacerbated by 
superimposed diabetes (18). Diabetes also impairs isometric 
relaxation of these papillary muscles to a greater extent than in 
nonhypertrophic muscles (17, 18). 
Configurational changes in the AP alone caused by diabetes may 
not be sufficient to influence contractile events in the heart. Our 
data also show that diabetes prolongs the AP to the same extent in 
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SHR and WKY papillary muscles (Table 3). While diabetes depresses 
2t 
cardiac function in the SHR (e.g., LV pressure and SR Ca uptake), 
it has no effect on the function of the WKY heart (11, 12, 57). 
Conversely, other authors have reported mechanical changes in heart 
muscle imposed by different pathological conditions (including 
hypertrophy and hypothyroidism) without concomitant alterations in 
the AP (32, 41, 51, 56). Collectively, these data must call into 
question the direct association of disrupted membrane potentials and 
mechanical function. The evidence obtained from the WKY strain 
suggests that intracellular events subsequent to the AP (e.g., SR 
2t Ca uptake and perhaps myosin ATPase activity) are the primary 
determinants of alterations in myocardial performance affected by 
diabetes in the SHR strain. 
Changes in APO due to either diabetes, hypothyroidism, or 
hypertrophy are generally independent of resting membrane potential 
(RP), AP amplitude (AMP) or rate of depolarization (Vmax; 3, 9, 10, 
17, 20, 47). Neither diabetes nor hypertrophy affected RP, AMP or 
V (Table 4); however, the values for these measurements differ 
max 
somewhat from previously published data. A papillary muscle RP 
typically ranges from -70 to -78 mV (17, 47, 56) yet the average RP 
for all groups in our study is approximately -65 mV (Table 4). The 
RP is primarily dependent on the activity of sarcolemma (SL) Nat/Kt 
ATPase, which is highly sensitive to temperature and metabolic 
disturbances (e.g., hypoxia). Sauviat and Feuvray (47) and Fein et 
al. (17) reported RP values of -60 mV from papillary muscle 
superfused with buffer below 30°c. Exposure to either hypoxic 
conditions or ouabain inhibits Nat/Kt ATPase activity and reduces 
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papillary muscle RP (2, 17). A reduced RP may partially inactivate 
the voltage-dependent Na+ channels which are primarily responsible 
for the initial depolarization. Often V is used as an indirect 
max 
index of Na+ channel conductance (50). Accordingly, low temperatures 
and metabolic inhibitors reduce V , and this might help explain a 
max 
nearly 5-fold decrease in our V values when compared to published 
max 
data. Decreased Nat/Kt ATPase activity may not, however, explain all 
of our discrepant results. Normal SHR (22 week-old) have 
significantly lower SL Nat/Kt ATPase and reduced ouabain sensitivity 
than do SL membranes from WKY (35), but do not differ with respect to 
either RP or V (Table 4; 56). The APO of hypoxic muscle is 
max 
characteristically shorter than the APO of normal muscle (24). 
Despite the deviations between our data and those of others, the APO 
of nondiabetic SHR and WKY are quantitatively similar to other 
published values (56). 
Treatment with either insulin or thyroid hormone prevents the 
diabetes-induced changes in AP configuration of SHR papillary muscle. 
The effectiveness of insulin treatment on the electrophysiological 
properties of diabetic SHR hearts is not surprising, since most of 
the in vivo metabolic changes are also preventable (Tables 1 and 2). 
However, until recently the hypothyroidism attending diabetes was 
thought to have only a minimal impact on cardiac mechanical function 
in the diabetic rat (6, 14, 21, 23, 53, 54). However LeGaye et al. 
(34) reported that treatment of diabetic normotensive rats with T3 
partially prevents the prolongation of atrial muscle AP. Our 
findings indicate that T3 completely prevents the delayed 
repolarization of papillary muscle in diabetic SHR. These data, 
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coupled with similar findings on mechanical and biochemical indices 
of function (11, 12, 42), strongly suggest that the thyroid hormone 
deficit is responsible, at least in part, for the diabetes-induced 
effects on SHR heart function. Preliminary results also show that T3 
treatment of diabetic RVH can prevent cardiac functional impairments 
in this model of hypertensive diabetic cardiomyopathy as well 
(unpublished observations). Thus, the presence of preexisting 
hypertrophy may influence myocardial dependence on thyroid hormone 
during the diabetic state. 
The cellular mechanisms by which insulin and T3 affect cardiac 
excitation contraction coupling are not understood. Insulin may 
influence cardiac function by improving metabolic activities; for 
example by increasing glucose availability, reducing fatty acid (FA) 
accumulation and protein wasting, or by changing sympathetic nerve 
activity (13). Even though a single daily injection of insulin does 
not always adequately control the serum hyperglycemia or BW loss in 
diabetic SHR, the hormone treatment is sufficient to maintain normal 
heart function (11). Rubinstein et al. (46), and more recently 
Rodrigues et al. (44), have also demonstrated that incomplete insulin 
therapy restores cardiac mechanical activity without fully correcting 
all metabolic changes associated with diabetes in the rat. 
Similarly, T3 treatment of diabetic SHR does not control the 
hyperglycemia or BW loss, yet effectively maintains normal cardiac 
performance ex vivo (Table 2, Table 3 and Figure l; 11, 12). It is 
possible that a portion of insulin's actions is secondary to that of 
thyroid hormone (52), since insulin treatment also prevents the 
attendant hypothyroidism of diabetes (11). 
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The AP configuration of diabetic SHR papillary muscle may be 
influenced directly or indirectly by T3 treatment. For example, 
thyroid hormone can decrease the density of ca 2+ channels in the rat 
ventricle (26), which would reduce the net inward current and enhance 
rates of repolarization. · 2+ By preventing depressed rates of Ca 
uptake by the SR, T3 treatment may reduce a transient inward current 
activated by intracellular ca 2+ (12). Diabetes-induced increase of 
intracellular and membrane-bound FA (13) may disrupt the electrical 
activity of the heart, particularly when glucose is not an available 
fuel source. Katz and Messineo (31) demonstrated that the 
accumulation of FA can influence the AP configuration when glucose 
availability is restricted. T3 treatment, known to increase glucose 
uptake and utilization by cardiac muscle (49), may prevent this 
impairment. 
To our knowledge, this is the first study showing that diabetes 
induces a prolongation of the AP in papillary muscle of the SHR, and 
that in vivo T3 treatment is as effective as insulin treatment in 
preventing this prolongation. T3 treatment in diabetic SHR not only 
prevents the impairments in cardiac electrophysiology, but also those 
relating to cardiac performance and a biochemical index of function 
(11, 12). Thus, thyroid hormone deficits may be an important 
component in the etiology of diabetic cardiomyopathy in SHR. 
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Table 1. Systolic arterial pressure and heart rates of nondiabetic and 
diabetic SHR and WKY rats. 
SAP (mmHq) HR (beats/min) 
Group (nl Week 0 Week 8 Week 0 Week 8 
llB. 
Nondiabetic ( 7) 198 .±. 20y 196 .±. 17y 399 .±. 19y 418 .±. 27y 
Diabetic (7) 198 ±. 10 140 ±. 12* 401 ±. 25 298 ±. 27* 
Diabetic + I ( 8) 194 ±. 24 185 ±. 22 381 ±. 27 378 ±. 31 
Diabetic + T3 ( 7) 189 .±. 16 201 .±. 12 383 .±. 26 438 .t 48 
m 
Nondiabetic (6) 144 ±. 16 142 ±. 19 333 ±. 26 307 ±. 32 
Diabetic ( 7) 141 ±. 16 134 ±. 18 328 ±. 20 283 ±. 24 
Values represent means ±. SD, obtained 8 weeks after initiation of diabetes or 
treatment. SAP, systolic arterial pressure; HR, heart rate; I, protamine zinc 
insulin; r 3, triiodothyronine. 
~Significantly different from the nondiabetic group (within strain). 
YSignificantly different from the nondiabetic WKY. 
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Table 2. Body and heart weights of nondiabetic and diabetic SHR and WKY rats. 
Group (n) 
WR. 
Nondiabetic ( 7) 
Diabetic ( 7) 
Diabetic + I ( 8) 
Diabetic + T3 ( 7) 
m 
Nondiabetic ( 6) 
Diabetic ( 7) 
338 
195 
327 
187 
BW 
(g) 
.±. 21y 
±. 25* 
±. 19 
.!. 12* 
385 ±. 21 
302 ±. 31* 
HW 
(mg) 
1.27 .±. 0.07 
0.70 ±. 0.11* 
1.15 ±. 0.08** 
0.83 .!. 0.12** 
1.38 ±. 0.25 
1. 09 ±. 0.27* 
LV/BW 
(mg/g) 
2.92 .±. 0.12 
2.60 ±. 0.48 
2.67 ±. 0.09 
3.12 ! 0.30 
2.57 ±. 4.25 
2.56 ±. 0.64 
LV/RV 
(mq/mg) 
5.43 ± 0.46y 
4.22 ±. 0.32* 
4.90 ±. 0.25** 
4.13 ! 0.29* 
3.84 ±. 0.52 
3.93 ±. 0.32 
Values represent means ±. SO, obtained 8 weeks after initiation of diabetes or 
treatment. BW, body weight; HW, heart weight; LV, left ventricular weight; RV, 
right ventricular weight; I, protamine zinc insulin; T3, triiodothyronine. 
*Significantly different from the nondiabetic group (within strain). 
**Significantly different from the nondiabetic and diabetic groups (within 
SHR). 
YSignificantly different from the nondiabetic WKY. 
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Table 3. Papillary muscle action potential duration of nondiabetic and 
d iabetic SHR and WKY rats. 
Group (n) 
~ 
Nondiabetic ( 7) 12.2 .±. 1.5 
Diabetic ( 7) 27.6 ±. 3.5* 
Diabetic + I ( 8) 11.4 .±. 1. 2 
Diabetic + Tl ( 7) 14.0 .±. 2.0 
m 
Nondiabetic (6) 8.2 ±. 2.0 
Diabetic ( 7) 28.9 ±. 5.9* 
16.5 .±. 1.8 
39.0 ±. 3.7* 
15.1 ±. 2. 0 
18.6 .±. 2.3 
11. 4 .±. 2 .1 
37.9 ±. 7.1* 
APD50 
(ms) 
24.8 ±. 2.2 
57.1 ±. 5.0* 
22.7 ±. 2.3 
26.5 .±. 2.8 
17.2 .±. 2.7 
54.7 ±. 9.8* 
39.5 ±. 2.6 
91. 9 ±. 7.8* 
36.2 ±. 3.6 
40.3 .±. 4.1 
28.5 .±. 3.4 
84 . 0 ±. 13 .8* 
Values represent means ±. SE, obtained 8 weeks after initiation of diabetes or 
treatment. Sample sizes reflect number of animals from which multiple fibers 
(4-10) were sampled and averaged. APD10-APD 75, action potential duration at 
10\-75\ repolarization; I, protaaine zinc insulin; T3, triiodothyronine. 
*Significantly different from the nondiabetic group (within strain). 
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Table 4. Papillary muscle membrane potential characteristics of nondiabetic 
and diabetic SHR and WKY rats. 
Group 
~ 
Nondiabetic 
Diabetic 
Diabetic + I 
Diabetic + T3 
m 
Nondiabetic 
Diabetic 
(n) 
(7) 
( 7) 
( 8) 
( 7) 
(6) 
( 7) 
RP 
(-mV) 
65.4 ±. 1.4 
61. 8 ±. l. 4 
64.6 ±. 1.0 
64.9 .± 0.8 
64.9 ±. 2.4 
65.2 ±. 2.0 
AMP 
(mV) 
79.0 ±. 2.5 
82.9 ±. 3.8 
80.4 ±. 1. 5 
80.7 .± 1. 9 
81.6 ±. 2.8 
84.l ±. l. 3 
Vmax 
(V/S) 
28 ±. 2 
22 ±. 3 
27 ±. 2 
26 + 1 
27 + 3 
28 ±. 2 
Values represent means ±. SE, obtained 8 weeks after initiation of diabetes or 
treatment. Sample sizes reflect number of animals from which multiple fibers 
(4-10) were sampled and averaged. RP, resting membrane potential; AMP, action 
potential amplitude; Vmax, maximum rate of rise; I, protamine zinc insulin; r3, 
triiodothyronine. 
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Figure 1: Representative papillary muscle action potentials (AP). 
(A) The AP were recorded from nondiabetic SHR (ND), diabetic SHR (D), 
nondiabetic WKY (NOW) and diabetic WKY (OW), and (B) from T3-treated 
diabetic SHR (D+T 3) and insulin-treated diabetic SHR (D+I). The 
individual AP were recorded from a single animal within each 
experimental group and were chosen because they best represented the 
average AP configuration as described in Table 3. 
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GENERAL DISCUSSION 
The results of this study can be summarized according to the 
original aims and hypotheses as follows: 
1) Untreated diabetes mellitus of 8 weeks duration caused a 
pronounced deficit in mechanical performance of spontaneously 
hypertensive rat (SHR). The depressed function in diabetic SHR 
hearts was not attributable to either malnutrition or a 
nonspecific effect of the diabetogen streptozotocin. Thyroid 
hormone treatment (in vivo) was nearly as effective as insulin 
treatment was in preventing the diabetes-induced 
cardiodepression in SHR. 
2) Diabetes impaired left ventricular (LV) relaxation and 
2+ Ca uptake by the sarcoplasmic reticulum (SR) in the SHR but 
not in the nonhypertensive Wistar Kyoto (WKY) rat. 
3) Thyroid hormone treatment, like insulin, completely 
prevented depressed rates of load-dependent relaxation and SR 
2+ Ca uptake in diabetic SHR hearts. 
4) Diabetes prolonged ventricular action potential (AP) to the 
same extent in SHR as it did in WKY rats, and the AP duration 
(APO) was similar in both nondiabetic strains. 
5) Either thyroid hormone or insulin treatment prevented the 
APO changes associated with diabetes in SHR papillary muscle. 
6) Chronic diabetes had the same cardiodepressive effects on 
mechanical performance in the renovascular hypertensive (RVH) 
rat as it had in the SHR (Appendix A). 
7) Either thyroid hormone or insulin treatment prevented 
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diabetes-induced mechanical impairments in RVH heart 
performance. 
Thus, these results support the central hypotheses of the study, with 
the following exception: The effects of chronic diabetes on APO of 
SHR papillary muscle were not more pronounced than they were on the 
APO of nonhypertrophic WKY muscle. 
The preexisting hypertrophy, rather than the etiology of 
hypertension, may be a primary factor influencing the exaggerated 
effects of diabetes on cardiac performance of hypertensive rats. The 
SHR and RVH are two experimental models which have been used to 
investigate the combined effects of diabetes and hypertrophy on 
cardiac function. Hypertension is induced in · the RVH by surgically 
imposing elevated plasma renin activity (Goldblatt 1934). The SHR 
strain is genetically predisposed to elevated arterial pressures, 
which is believed to stem, in part, from enhanced central sympathetic 
activity (Yamori 1975) and is characterized by normal or below normal 
plasma renin activity (Sonkodi and Abraham 1988). One obvious common 
denominator of the RVH and SHR models of hypertension is the presence 
of LV hypertrophy. The presence of LV hypertrophy alone is not 
always associated with impaired cardiac mechanical performance 
(Pfeffer et al. 1979; Capasso et al. 1986; Rodgers et al. 1986). The 
results of this study provide additional evidence that cardiac 
function in 23 week-old SHR is still within the adaptive phase of 
hypertrophy. Cardiac mechanical performance is also normal after 12 
weeks of imposed hypertension in 23 week-old RVH (Appendix A). 
However, when diabetes coexists with LV hypertrophy (in either SHR or 
RVH), LV contraction and relaxation of perfused hearts are depressed 
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more than when diabetes is imposed on nonhypertrophic hearts (Rodgers 
1986; Rodrigues and HcNeill 1986; Davidoff and Rodgers; Davidoff et 
al.; Appendix A). Isometric relaxation is also prolonged in 
papillary muscles from diabetic RVH (Fein et al. 1984). The effects 
of diabetes on cardiac function in hypertensive rats is independent 
of either sustained hypertension or LV hypertrophy. Diabetes 
depresses SAP in SHR without significantly changing SAP in RVH 
(Rodgers 1986; Davidoff and Rodgers: Appendix A). The depressor 
effects of diabetes is SHR in not always correlated with reversal of 
LV hypertrophy (Rodgers 1986; Davidoff and Rodgers; Davidoff et al.; 
Davidoff and Rodgers). Diabetes, however, consistently impairs 
mechanical performance in both SHR and RVH but it has no effect on 
cardiac function in nonhypertensive, nonhypertrophic WKY rats. 
Diabetes depresses LV pressure generation in nonhypertensive 
Sprague-Dawley rat hearts, but the magnitude of diabetes-induced 
effects are markedly greater in SHR (Rodgers 1986). Therefore, the 
key characteristic, which accounts for the exacerbation of the 
cardiodepressant effects of diabetes, seems to be preexisiting LV 
hypertrophy. 
The predisposition of LV hypertrophy on cardiodepressive effects 
of diabetes involves the reticular elements of the myocyte. A 
biochemical defect often found to be characteristic of diabetic 
myocardium is a depressed rate of ca2+ sequestration by SR microsomes 
2+ (Dhalla et al. 1985). A reduced rate of SR Ca uptake is generally 
associated with impaired load-dependent relaxation (Brutsaert et al. 
1980; Bers 1985; see also discussion in Davidoff et al.). Proposed 
mechanisms include reductions in either the density or the activity 
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2+ 2+ 
of Ca -Mg ATPase {Penpargkul et al. 1981; Ganguly et al. 1983; 
Schaffer et al. 1989), alterations in membrane lipid profiles 
(Lopaschuk et al. 1983; Ganguly et al. 1983; Kim and LaBella 1988), 
or changes in the degree of membrane phosphorylation (Kranias et al. 
1988). Until now, studies of this kind have been restricted to 
nonhypertensive, nonhypertrophic models. The data presented in this 
study suggest, however, _that the adverse effects of diabetes on left 
ventricular SR ca 2+ uptake activity are exacerbated by preexisting 
hypertrophy. Thus, diabetes of equal duration and severity - as 
measured by serum glucose and insulin levels - depresses SR ca 2+ 
uptake of SHR left ventricles, but has no effect in the 
nonhypertensive WKY strain. These results extend those of earlier 
studies which had demonstrated that the detrimental effects of 
chronic diabetes on various indices of cardiac mechanical activity 
are more pronounced in hypertrophic than in nonhypertrophic 
ventricles of both the SHR and RVH models (Fein et al 1984; Rodrigues 
and McNeill 1986; Rodgers 1986; Davidoff and Rodgers; Appendix A). 
Increased duration of the cardiac AP may be linked to disrupted 
mechanical activity in both diabetic {Fein et al. 1983; Nordin et al. 
1985) and hypertrophic myocardium {Gulch et al. 1979; Heller and 
Stauffer 1981; Aronson and Keung 1983; Thollon et al. 1985; Capasso 
et al. 1986). There is a considerable amount of evidence to suggest 
that calcium metabolism is abnormal in either diabetic or 
hypertrophic myocardium. Heart muscle from both disease states may 
exhibit increased frequency of afterdepolarizations and triggered 
activity {Fein et al. 1983; Nordin et al. 1985), altered SR or 
sarcolemmal calcium fluxes (Penpargkul et al. 1980; Limas and Cohen 
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1979; Rodgers et al. 1986; Andrawis et al. 1988; Nakanishi et al. 
1989; Davidoff et al.), and beneficial responses to calcium channel 
blockers (Afzal et al. 1988, 1989). In many of these studies, 
depressed mechanical activity of muscle have been linked to elevated 
intracellular calcium concentrations (Aronson and Keung 1983; Nordin 
et al. 1985; Afzal et al . 1988; Afzal et al. 1989), which in turn is 
assumed to be toxic to the cell (Dhalla et al. 1985; Andrawis et al. 
1988). The influx of calcium during the cardiac AP probably 
increases with delayed repolarization and may contribute to changes 
in metabolism and mechanical functions. It has been suggested that 
the net inward current during the plateau phase is increased in some 
models of hypertrophy (Kleiman and Houser 1988), is perhaps due to a 
decrease in outward Kt current . The time course of the AP of 
hypertrophic muscle appears to be prolonged by a depressed rate of 
inactivation of the slow inward (Ca 2+J current, when compared to 
normal muscle cells (Aronson and Keung 1983; Kleiman and Houser 
1988). It is still not clear, however, whether the underlying 
mechanisms which prolong the AP in cardiac muscle of both diabetic 
and hypertensive animals have a common ionic basis. 
The cardiac APD in several hypertensive animal models is 
significantly prolonged relative to that in normotensive animals. 
Aortic stenosis, renal artery constriction and chemically-induced 
hypertension promote ventricular hypertrophy and changes in AP 
configuration to varying degrees (Aronson 1980; Heller and Stauffer 
1981; Thollon et al. 1985; Capasso et al. 1986; Nordin et al. 1989). 
The hypertrophic papillary muscle of SHR (Kawamura et al. 1976) does 
not, however, exhibit longer repolarization times when compared to 
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the nonhypertrophic WKY (Davidoff and Rodgers). While there were no 
statistical differences between APO of nondiabetic SHR and WKY 
papillary muscle in this study, there was an apparent trend toward 
higher APO values in SHR. Larger samples sizes may support 
statistical differences. Hayashi and Shibata (1974) recorded 
ventricular AP from Langendorf perfused hearts of SHR and WKY. It is 
not clear from their data whether the average APDlOO is significantly 
greater for SHR than for WKY (mean (ms) ±SE (n=5), 104.0 ± 3.1 and 
93.9 i 3.2, respectively). Volkmann et al. (1989) recently reported 
APD80 values for papillary muscle in SHR and WKY of 37.7 ± 3.0 and 
33.9 ± 1.8, respectively (meant SE, n= 9 and 10). The differences 
in APO between SHR and WKY are not as apparent as they are in other 
models of hypertrophy, but whether the discrepancies are related to 
the genetic strain, etiology or duration of hypertrophy, or other 
factors, remain to be tested. 
These results suggest that alterations in electrophysiological 
characteristics of ventricular muscle may contribute to the etiology 
of diabetic cardiomyopathy in SHR. The data in this study also show, 
however, that diabetes prolongs the AP to the same extent in SHR and 
WKY papillary muscles, but depresses cardiac function only in the SHR 
(e.g., LV pressure and SR ca2+ uptake; Yammamoto and Nakai 1988; 
Davidoff and Rodgers; Davidoff et al.). In other normotensive rat 
strains, however, diabetes prolongs APO and impairs mechanical 
function (Fein et al. 1980; Fein et al. 1983; Sauviat and Feuvray 
1985). While the dissociation of electrical and mechanical events is 
not common, it is not without precedent. Indices of isometric 
contraction but not AP configuration of rat papillary muscles were 
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affected by chemically-induced thyroidectomy (6-7 weeks) and 
thyrotoxic doses of T3 (2 weeks; Poggesi et al. 1987). An increase 
in isometric tension in SHR papillary muscle did not correspond to a 
change in AP configuration when compared to these measurements in 
WKY muscle (Volkmann et al. 1989). Collectively, these data must 
call into question the direct association of disrupted membrane 
potentials and mechanical function. The evidence obtained from the 
WKY strain suggests that intracellular events subsequent to the AP 
2+ (e.g., SR Ca uptake and perhaps myosin ATPase activity) are the 
primary determinants of alterations in myocardial performance 
affected by diabetes in both hypertensive and normotensive rat 
strains. 
The mechanism responsible for the apparent interaction between 
diabetes and LV hypertrophy with respect to cardiac function remains 
a matter of speculation. Metabolic derangements in the diabetic 
heart include decreases in lipolytic activity, fatty acid (FA) 
oxidation and glucose utilization (Paulson and Crass 1982; Vary and 
Neely 1982; Kobayashi and Neely 1983; Dhalla et al. 1985). These in 
turn are linked to changes in energy substrate availability, membrane 
integrity and function in the heart (Dhalla et al. 1985). 
Hypertrophy may exacerbate these metabolic effects. Like diabetes, 
LV hypertrophy is associated with alterations in lipid metabolism 
(Reibel et al. 1983; Reibel et al. 1987; Fujii et al. 1988; Rodrigues 
et al. 1988), restricted fuel source availability (Savabi 1988; 
Wexler et al. 1988), and changes in sarcolemmal (SL) ion transport 
(Lee et al. 1983; Nakanishi et al 1989). Hypertrophic muscle may 
undergo compensatory intracellular changes to accommodate elevated 
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workloads and reduced coronary reserves (Shimamoto et al. 1982; Tubau 
et al. 1989). For example, an increase demand for FA oxidation, as 
the primary fuel source, may be met by increased myocardial carnitine 
content (Foster et al. 1985; Reibel et al. 1987). · Changes in SL ion 
pump activities may enhance intracellular ca 2+ concentration and 
augment myocardial contractility. These and other cellular 
mechanisms may combine to predispose the hypertrophic ventricle to 
membrane-disrupting effects of diabetes. 
A low thyroid state might contribute significantly to changes in 
cardiac performance of diabetic SHR. Methimazole treatment of SHR 
causes a depression in heart performance ex vivo that is 
qualitatively similar to the effects of diabetes, though lesser in 
magnitude (Rodgers 1986). These results were confirmed in a later 
study of the effects of surgical thyroidectomy on cardiac function in 
SHR (Rodgers and McNeill 1986). Based on these observations, it was 
expected that triiodothyronine (T3 ) treatment of diabetic SHR might 
reduce the magnitude of the subsequent impairment in mechanical 
function. It was somewhat ~urprising that T3 was almost as effective 
as insulin was in preventing the depressions in measurements of heart 
function, including pressure generation, rates of contraction and 
relaxation and stroke work. 
The present results differ to some extent from previous reports 
of the effects of T3 treatment on cardiac function and hemodynamic' 
measurements in normotensive rat strains. Higher doses of T3 (25-30 
µg/kg/day), administered to diabetic Wistar rats for 6 weeks, failed 
to prevent the cardiac functional impairments (Tahiliani and McNeil! 
1984), but when given to diabetic Sprague-Dawley (SD) rats for only 5 
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days, restored mechanical indices of cardiac function to normal 
(Garber et al 1983). In the latter study, lower doses of T3 
(considered to be more appropriate for replacement therapy of 
hypothyroidism) were not completely effective. In a recent report, 
Barbee et al. (1988) found that approximately 4 µg T3 per rat per day 
for 3 weeks (by subcutaneous pellet implant) did not improve 
performance of unpaced hearts from diabetic SD rats. However, these 
investigators also failed to demonstrate any effect of diabetes on 
paced heart function. For the present studies, the dose of T3 was 
selected according to its ability to restore to normal the depressed 
heart rate (HR) in vivo, an index which is a sensitive indirect 
indicator of thyroid status. This turned out to be about 2-3 fold 
greater than "physiologic" replacement doses in nonhypertensive rat 
strains (Dillmann 1982). The T3 dose used herein did not appear, 
however, to impose a hyperthyroid condition in diabetic SHR. This 
conclusion is based on the following: 1) The dose used did not 
elevate serum T3 levels above normal, when measured at the same time 
point after injection, in either the diabetic or nondiabetic SHR 
groups (Davidoff and Rodgers); 2) The same dose given to nondiabetic 
SHR had no effect on heart and body weights, or on SAP or HR in vivo; 
and 3) T3 treatment of nondiabetic SHR had no effect on any of the 
indices of cardiac performance ex vivo. Although T3 treatment 
reduced body weights of the diabetic SHR, it had no effect on this 
measurement in the nondiabetic control group. 
The difference in the effectiveness of T3 in diabetic SHR 
compared to normotensive rats are probably related to the elevated 
arterial pressure of SHR, and not to differences related specifically 
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to the genetic strain. Treatment with T3 prevents the 
cardiodepression in diabetic RVH as well as in diabetic SHR (Appendix 
A). It is possible that hypertrophy, stimulated by elevated arterial 
pressure in both models, may increase cardiac susceptibility to a 
number of stresses including those imposed by diabetes (Factor et al. 
1981; Rodgers 1986; Rodrigues and McNeill 1986), hypothyroidism 
(Rodgers et al. 1986), or ischemia (Mochizuki et al. 1986). This 
suggests that the hypothyroidism accompanying diabetes has a more 
profound cardiovascular effect in animals with elevated arterial 
pressure, and that hypertrophied myocardium may be functionally more 
dependent upon thyroid status than is nonhypertrophic heart muscle. 
There are a number of mechanisms by which T3 therapy might 
effectively prevent the cardiac functional impairments of diabetes, 
especially in hypertrophic heart muscle. Thyroid hormone may relieve 
some of the metabolic stresses by increasing myocardial utilization 
of FA and decreasing FA accumulation (Markin et al. 1983; Muller and 
Seitz 1984a; Tanaka et al. 1985). Enhancing plasma lipid clearance 
with methionine treatment, for instances, improves cardiac 
performance in diabetic Wistar rats (Heyliger et al 1986). The 
vasodilator hydralazine reduces serum lipids in diabetic Wistars and 
improves cardiac function of isolated working hearts (Rodrigues et 
al. 1986). Interestingly, hydralazine treatment also corrects the 
hypothyroid state in these diabetic rats. Other actions of thyroid 
hormone include stimulation of glucose uptake and cellular metabolism 
(Muller and Seitz 1984b; Tanaka et al. 1985; Gordon et al. 1986; 
Segal 1989). T3 directly stimulates glucose uptake in several rat 
tissues including the heart, by enhancing the activity of the plasma 
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membrane transport mechanism (Segal 1989). Treatment of diabetic SHR 
and RVH with T3 may increase the availability of glucose and lipids 
as energy substrates and reduce FA accumulation, which would help to 
account for the improved cardiac function. This and other related 
metabolic actions may be more crucial, and more apparent, ·against a 
background of high workloads and associated metabolic demand . 
A common biochemical change observed in hearts from either 
diabetic, hypertensive or hypothyroid animals is depressed SR ca 2+ 
uptake, which correlates with impaired myocardial relaxation (Suko 
1973; Dhalla et al. 1985; Rodgers et al. 1986). Thyroid hormone 
treatment does not restore SR ca 2+ uptake or LV function in diabetic 
normotensive rats (Ganguly et al. 1983; Tahiliani and McNeil! 1984), 
yet is completely effective on diabetic hypertensive muscle (Davidoff 
et al.). The presence of hypertrophy may account for the 
differential effects of diabetes and T3 treatment on cardiac 
function, in part because of alterations in lipid metabolism (see 
2+ 2+ 
above). The acute effects of T3 on Ca -Mg ATPases are profoundly 
influenced by the lipid environment (Galo et al. 1981). Because 
hypertrophy (Petkov et al. 1988), hypothyroidism (Galo et al. 1981) 
and diabetes (Gudbjarason et al. 1987) all affect membrane lipid 
composition, it seems reasonable to hypothesize that different 
combinations of these pathophysiologic conditions will have variable 
influences on the subsequent effects of T3 administration. In 
normotensive rats, myoinositol coadministration increases the 
therapeutic efficacy of T3 in diabetic cardiomyopathy (Xiang et al. 
1988) . Fatty acyl esters of carnitine may be especially important. 
Enhanced incorporation of long chain acyl carnitines (LCAC) into the 
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2+ SR membrane is correlated with depressed rates of Ca uptake in 
diabetes (Lopaschuk et al. 1983) and r 3 treatment decreases LCAC 
levels in SR membranes (Black et al. 1988). Another potential 
2+ mechanism undoubtedly involves the regulation of SR Ca pump 
activity by thyroid hormone. Chronically, r 3 probably increases the 
2+ . 2+ 2+ 
rate of SR Ca uptake by accelerating the synthesis of Ca -Mg 
ATPase enzyme molecules. Hypothyroidism has opposite effects on 
these measurements (Rohrer and Dillmann 1988). 
Disruptions in myocardial excitation-contraction coupling 
characteristic of diabetes, hypertension and hypothyroidism (Fein et 
al 1983; Nordin et al. 1985; Capasso et al 1986) include prolongation 
of the cardiac AP. T3 treatment prevents diabetes-induced 
alterations in SHR cardiac AP, and thus normalizes the first step 
leading to mechanical activity. The AP configuration of diabetic SHR 
papillary muscle may be influenced directly or indirectly by T3 
treatment. For example, thyroid hormone can decrease the . density of 
ca
2
+ channels in the rat ventricle (Hawthorn et al. 1988), which 
would reduce the net inward current and enhance rates of 
repolarization. Similarly, r 3 treatment may inhibit a transient 
inward current activated by intracellular ca 2+, by restoring normal 
rates of SR ca 2+ uptake (T 3 prevents depression of ca
2+ uptake by the 
SR in diabetic SHR; Davidoff et al.). Diabetes-induced increase of 
FA (Dhalla et al. 1985) may disrupt the electrical activity of the 
heart, particularly when glucose is not an available fuel source. 
Katz and Messineo (1981) demonstrated that the accumulation of FA can 
influence the AP configuration when glucose availability is 
restricted. T3 treatment, shown to increase glucose uptake and 
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utilization by cardiac muscle (Segal 1989), may prevent this 
impairment. 
Another common manifestation of diabetes, hypertrophy and 
hypothyroidism in rat ventricular muscle is a shift from the 
predominant v1 to the v3 myosin isozyme (Malhotra et al. 1981; 
Mercardier et al. 1981; Dillmann 1982; Garber et al. 1983; Morkin et 
al 1983; Rupp and Jacob 1986; Schaffer et al. 1989). By extension, 
the effects of hypertension and diabetes (with or without 
hypothyroidism) on myosin isozyme profiles may be additive, but this 
hypothesis has not been tested. Thyroid hormone treatment in animals 
with a normally higher distribution of v3 than v1 promotes a shift to 
the more active v1 form (Morkin et al. 1983; Williams and Ianuzzo 
1988). Garber et al. (1983) were able to prevent the 
diabetes-induced v3 shift with T3 treatment in SD rats. T3 
administration to diabetic SHR and RVH may also change the ratio of 
myosin isozyme activity in favor of v1 and this may in turn help to 
explain the increased rate of contractility in these groups (Davidoff 
and Rodgers; Appendix A). The effects of diabetes and T3 treatment 
on ventricular myosin isozyme distribution in SHR and RVH are 
presently being investigated in this laboratory. 
Several alternative interpretations of the results of this study 
could be eliminated by the control studies. Amelioration of the 
cardiodepression and mortality by either insulin or T3 treatment and 
by pretreatment with the glucose analog 3-0-methylglucose (Ramanadham 
et al. 1987), ruled out the possibility that direct cardiotoxicity of 
streptozotocin contributed to the morbidity and mortality of diabetes 
in either SHR or RVH. Neither malnutrition nor reduced heart mass 
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alone could account for the observed cardiodepressive effects of 
diabetes, since performance was not impaired in either of the food 
restricted groups (Davidoff and Rodgers; Appendix A). 
Complete glycemic control was not necessary to preserve cardiac 
function with diabetes. Treatment with either lente insulin or 
protamine zinc insulin (PZI) effectively maintained cardiac pump 
2+ function and SR Ca uptake, without normalizing serum glucose values 
of diabetic SHR (Davidoff and Rodgers; Davidoff et al.). Rubinstein 
et al. (1984) and Rodrigues et al. (1989) reported similar 
cardiovascular benefits from graded insulin treatment of normotensive 
diabetic rats, without complete normalization of blood glucose. 
2+ Lopaschuk et al. (1983) restored SR Ca uptake in diabetic Wistars 
with PZI treatment but did not completely restore blood glucose 
concentrations to normal levels. Strict glycemic control in humans 
also does not appear to be necessary for the prevention of diabetic 
nephropathies (Dodson and Horton 1988). T3 replacement therapy in 
the diabetic SHR and RVH did not adequately control the hyperglycemia 
or hypoinsulinemia, yet effectively restored cardiac function 
(Davidoff and Rodgers; Davidoff et al.; Appendix A). T3 treatment 
failed to reverse the weight loss incurred by diabetes while in 
general insulin · treatment only partially restored body and heart 
weights. 
The ability of T3 to restore SAP of diabetic SHR as effectively 
as insulin did suggests strongly that hypothyroidism contributes to 
the depressor effect of diabetes in this model. The results of 
earlier studies also indicated that thyroid hormone is an important 
regulator of arterial pressure in SHR. Thyroidectomy of young SHR 
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prevents the development of hypertension in these animals (Rioux and 
Berkowitz 1977; Rodgers and McNeill 1986). Increased total 
peripheral resistance (TPR) is the primary factor contributing to SHR 
hypertension (Pfeffer and Frohlich 1973). Thus, the decline in SAP 
of diabetic SHR may be associated with a fall in TPR. Results 
reported by Yamamoto and Nakai (1988) seem to show that moderate 
diabetes reduces TPR (estimated by their cardiac index and mean 
arterial pressure values) of SHR by about 10-20%, depending on the 
duration of diabetes. Alternatively, the depressor effect of 
diabetes on SHR may be primarily cardiogenic. As mentioned earlier, 
T3 treatment restored cardiac function ex vivo to near normal in 
diabetic SHR. Tsujimoto and Hashimoto (1986) attributed most of the 
rise in SAP of T3-induced hyperthyroid rats to the cardiac, rather 
than the vascular, effects of T3. Some of the in vivo hernodynamic 
effects of diabetes in SHR do not occur in RVH (Appendix A). 
Diabetes does not produce a reduction in SAP in RVH, but it does 
depress cardiac function. These observations lend additional support 
to suggest that there are direct myocardial effects of diabetes and 
the attendant hypothyroidism that are independent of hemodynarnic 
changes in vivo. 
Treatment with T3, like insulin, corrects the bradycardia of 
diabetic SHR. The bradycardia associated with either diabetes or 
hypothyroidism has been attributed, at least in part, to depressed 
myocardial responsiveness to adrenergic stimulation (Bilezikian and 
Loeb 1983; Gotzsche 1986). Both hypertrophic (Limas and Limas 1987) 
and diabetic (Heyliger et al. 1982; Kashiwagi et al. 1989) myocardium 
have been shown to possess a lower density of functional 
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6-adrenoceptors. Both insulin and T3 may be involved in the 
regulation of cardiac B-adrenoceptor density (Hawthorn et al. 1988). 
Insulin may act indirectly, and possibly completely, by restoring 
serum T3 levels (Davidoff and Rodgers; Davidoff et al.; Appendix A). 
Depressed myocardial a-adrenoceptor numbers of diabetic SD rats are 
restored to normal with either insulin or T4 treatment, while those 
of thyroidectomized diabetic rats are not affected by insulin 
treatment alone (Sundaresan et al. 1984). The chronotropic action of 
T3 in vivo may also involve a direct effect of the hormone on 
pacemaker cells (Kessler-Icekson 1988). The available evidence 
implies that perhaps all of the bradycardia associated with 
experimental diabetes, in the presence or absence of hypertension, 
can be attributed to the attendant hypothyroidism. 
In conclusion, the results presented herein show that diabetes 
impairs cardiac function to a greater extent in the SHR and the RVH 
rat than in the normotensive WKY rat. Diabetes depresses LV function 
(contraction and relaxation) in these hypertensive rats without 
dramatically affecting function in normotensive strains (Rodgers 
1986; Rodrigues and HcNeill 1986; Davidoff and Rodgers; Davidoff et 
al. l. 2+ Reduced rates of Ca uptake by the SR (Davidoff et al.) from 
diabetic SHR hearts probably contribute to these mechanical deficits. 
The effects of diabetes on the LV AP are not consistent with those on 
performance, since AP configuration is altered comparably in both SHR 
and WKY papillary muscles. It appears that in hypertensive rats 
intracellular events subsequent to the cardiac AP are more 
susceptible to the adverse effects of diabetes than in normotensive 
rats. 
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The results of this study also show that the cardiac impairments 
associated with diabetes in either the SHR or RVH can be prevented by 
T3 treatment. This is the first known account of a moderate dose of 
T3 successfully restoring cardiac function, including electrical, 
biochemical and mechanical events, in experimental diabetes. In 
addition, T3 treatment, like insulin, prevents the fall in arterial 
pressure and bradycardia induced by diabetes in the SHR in vivo, and 
either reduces or delays mortality. The results suggest that 
attendant hypothyroidism may play a more significant role in the 
development of diabetic cardiomyopathy in the presence of LV 
hypertrophy than it does in nonhypertrophic muscle. 
Diabetes mellitus is a heterogeneous disease and is 
subclassified by the National Diabetes Data Group as either one of 
the following: Type I (insulin-dependent diabetes mellitus or !DOM); 
Type II (non-insulin dependent diabetes mellitus or NIDDM); 
gestational diabetes; impaired glucose tolerance; or secondary 
diabetes. These results may have some clinical applicability 
particularly for IDDM patients. Hypertension apparently occurs more 
frequently among diabetic patients than in the general population 
(Fuller 1985; Sprafka et al. 1988; Bell 1989). It is often regarded 
as an important risk factor for the higher cardiovascular morbidity 
and mortality in this group (Kannel et al. 1974; Fuller 1985; Sprafka 
et al. 1988; Bell 1989). The incidence of impaired thyroid function 
among diabetics may be as high as 30\, is most severe during poor 
metabolic control, and is most evident in IDDH (Bagchi 1982). While 
diabetic patients with hypothyroidism may be at increased risk of 
cardiovascular morbidity and mortality (Whittingham et al. 1971), 
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this risk may be further intensified by hypertension. Supplemental 
thyroid hormone treatment in conjunction with insulin administration 
might provide additional therapeutic cardiovascular benefits, in 
patients with poorly controlled insulin-dependent diabetes 
complicated by attending hypertension and hypothyroidism. 
Future studies designed to provide additional information about 
the adverse effects of diabetes on hypertrophic myocardium and the 
mechanisms by which the attending hypothyroidism influence this 
dysfunction may include: 
Cellular mechanisms involved in the development of diabetic 
cardiomyopathy in the hypertrophic heart can be further characterized 
by studying, for example, ventricular myosin isozyme distributions, 
individual ionic currents in voltage-clamped isolated myocytes, and 
specific enzyme activities associated with sarcolemmal, mitochondrial 
and SR membranes. There are other experimental animal models that 
could be used to extend our knowledge about the adverse effects of 
diabetes on hypertrophic heart function (including mechanical, 
biochemical and electrophysiological indices of function). A few of 
these alternative models are described below. 
Hyperlipidemia is another prominent cardiovascular risk factor 
in diabetic patients with hypertension (Tzagournis 1989). 
Abnormalities in lipid metabolism may account for depressed cardiac 
function in SHR and perhaps in RVH. Diabetes induces hyperlipidemia 
in serum of SHR without affecting serum lipid values of WKY rats 
(Rodrigues and McNeill 1986). Cardiac function, serum lipid 
profiles, as well as phospholipid content could be assessed in 
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diabetic hypertensive rats treated with lipolytic agents. 
Antihypertensive therapy in diabetic patients and in diabetic SHR 
also reduces the accumulation of some plasma lipids which may account 
for improved cardiac performance (Tzagournis 1989j Rodrigues et al. 
1986). 
The cardiodepressive effects of diabetes may not be as severe in 
the SHR in the absence of preexisting hypertrophy. Antihypertensive 
treatment of SHR can reverse or prevent LV hypertrophy (Sen 1983). 
The cardiovascular effects of diabetes in nonhypertrophic SHR hearts 
could be studied by pretreating SHR with antihypertensive agents 
(Ruskoaho 1984). Chronic diabetes coupled with developing 
hypertension and LV hypertrophy may have different effects on cardiac 
function than when diabetes is superimposed on preexisting LV 
hypertrophy. Injection of streptozotocin in neonatal SHR causes 
diabetes mellitus without interfering with the onset of hypertension 
(Iwase et al. 1987a and 1987b). Simultaneous induction of diabetes 
and renovascular hypertension may be an alternative approach. Since 
hypertension often coincides with, but may not precede, diabetes, the 
use these experimental models could provide additional information 
about the cardiovascular manifestations characteristic of clinical 
diabetes. 
Hyperglycemia is a predominant metabolic disturbance of diabetes 
which results in an increase in intracellular glucose concentration 
in tissues where glucose uptake is insulin independent (e.g., liver, 
brain and kidney). In the presence of too much intracellular 
glucose, aldose reductase metabolizes glucose, ultimately forming 
copious amounts of sorbitol which promotes hypertonicity. Clinicians 
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are presently investigating the therapeutic benefits of aldose 
reductase inhibitors (e.g., tolrestat and sorbinil) in order to 
minimize the accumulation of the toxic glucose metabolites (see 
Swonger and Matejski 1988). Diabetes reduces glucose transport into 
cardiac tissue (Segal 1989), therefore, treatment with an aldose 
reductase inhibitor would most likely not have direct beneficial 
effects on cardiac function. However, these drugs may provide 
additional indirect protection to the cardiovascular system during 
poorly controlled diabetes by improving heptatic, renal and neural 
functions. 
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APPENDIX A: cardiac Performance of Diabetic RVH Rats 
- 139 -
SUMMARY 
Diabetes markedly depresses cardiac function in the 
spontaneously hypertensive rat (SHR). A low thyroid state appears to 
contribute to the impaired mechanical function of diabetic SHR 
hearts. In order to determine whether cardiac dysfunction is 
specific for the diabetic SHR, cardiac performance was assessed in 
diabetic renovascular hypertensive (RVH) rats. The 2-kidney, 1-clip 
procedure was used to produce hypertension in 11 week-old Wistar 
Kyoto (WKY) rats. Four weeks after surgery, chronic diabetes was 
chemically-induced by a single tail vein injection of streptozotocin 
(50 mg/kg). A subgroup of diabetic RVH were treated with either 
protamine zinc insulin (I; 10 U/kg/day) or triiodothyronine (T3; 8-10 
µg/kg/day). Other control groups included; nondiabetic RVH treated 
with same T3 dose as the diabetic group, food-restricted nondiabetic 
RVH, and diabetic and nondiabetic normotensive WKY rats. Weekly in 
vivo systolic arterial pressure (SAP) and heart rate (HR) were 
recorded throughout the study. The type of data collected and the 
manner in which it was analyzed was similar to the data presented in 
Davidoff and Rodgers. In brief, 8 weeks after the induction of 
diabetes animals were sacrificed, serum samples were collected and 
mechanical performance of isolated working hearts were assessed. 
Following the acquisition of cardiac performance data, wet heart 
weights, including whole heart (HW), left ventricular (LV) and right 
ventricular (RV) weights, were recorded. Hypertension in RVH was 
characterized by elevated SAP and HR when compared to WKY. Diabetes 
depressed HR only in RVH rat but had no effect on SAP in either RVH 
or WKY. Either insulin or T3 treatment prevented the drop in HR in 
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diabetic RVH. Diabetes impaired LV pressure generation and rates of 
contraction and relaxation in RVH but it had no effect on these 
measurements in WKY. T3 treatment was as effective as insulin was in 
preventing cardiac depression in diabetic RVH with one exception: 
The rate of LV pressure generation was significantly ' higher in 
T3-treated diabetic RVH than it was in untreated diabetic RVH, but 
the rate of LV pressure generation was also significantly lower in 
T3-treated diabetic RVH than it was in nondiabetic RVH. The cardiac 
performance in nondiabetic RVH was similar to nondiabetic WKY. The 
results provide additional evidence that hypertrophy, induced by 12 
weeks of RVH does not adversely affect mechanical function in the 
isolated working heart. Diabetes impairs cardiac function the the 
hypertensive, hypertrophic RVH but it does not affect function in the 
nonhypertensive, nonhypertrophic WKY. Hypertrophy may predispose the 
myocardium to the adverse effects of diabetes. Furthermore, the 
attendant hypothyroidism may contribute to the functional deficits 
characteristic of the diabetic hypertrophic heart. 
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Table 1. Serum glucose, insulin, triiodothyronine and thyroxine levels of 
nondiabetic and diabetic RVH and WKY rats. 
Group 
Nondiabetic 
Diabetic 
Diabetic + T3 
Diabetic + I 
Nondiabetic + T3 
Nondiabetic FR 
Nondiabetic 
n 
11 
9 
7 
8 
5 
5 
13 
Glucose 
(mg/dl) 
127 .t 
500 !. 
20 
44 
693 .t 150 
176 ±. 76 
168 
.t 33 
172 + 22 
140 ±. 40 
* 
** 
Insulin 
(J.IU/ml) 
77 .t 56 
* 10 !. 8 
* 26 .t 12 
273 ±. 86 
84 ± 25 
* 36 .t 8 
74 ±. 22 
T 
( ng}dll 
72 .t 131 5.09 .t 1. 44 
* 38 !. 10 2.98 !. 1.02 
116 ± 76 0.42 ± 0.41 
86 ±. 12 5.36 ±. 1.38 
397 ± 258* 0.33 ± 0.10 
74 .t 13 3.63 ± 1.04 
87 ±. 12 5.19 ±. 1.05 
* 
tt 
** 
* 
* * * * Diabetic 9 499 !. 103 18 !. 9 39 ±.13 2.35 !,.0.78 
Values areans ±. SD, obtained 8 weeks after initiation of diabetes or treatment. 
T3, triiodothyronine; T4, thyroxine; I, insulin; FR, food restricted. 
Significantly different from the nondiabetic group (within group). 
tt Significantly different from the nondiabetic and diabetic groups. 
1 Significantly different from the nondiabetic WKY. 
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TABLE 2. Body and heart weights of nondiabetic and diabetic RVH and WXY rats. 
Group n BW 
(g) 
HW 
(mg) 
LV/BW 
(mq/g) 
LV/RV 
(mg/mg) 
Nondiabetic 11 329 ± 531 1556 ± 1951 
y y 3.77 i 0.57 5.07 ± 0.62 
Diabetic 
Diabetic + T3 
Diabetic + I 
Nondiabetic + T3 
Nondiabetic FR 
Nondiabetic 
Diabetic 
9 
7 
8 
5 
5 
13 
9 
t 
* 266 !.. 27 1219 !.. 88 3.57 !.. 0.35 5.02 !.. 0.39 
* * * 225 ± 50 1258 ± 209 4.48 i 0.52 4.92 i 0.90 
356 ±. 48 1508 ±. 125 3.44 ±. 0.55 5.17 ±. 0.63 
* 353 ± 24 1628 ± 146 3.59 i 0.46 4.52 ± 0.86 
* 294 ± 38 1182 ± 59 3.29 i 0.48 5.27 i 0.48 
376 ±. 28 1428 ±. 182 2.92 ±. 0.15 4.57 ±. 0.76 
* * 290 !.. 34 1070 ±. 75 2.91 ±. 0.22 4.58 ±. 0.24 
Values areans ±. SD, obtained 8 weeks after initiation of diabetes or treatment. 
r 3, triiodothyronine; I, insulin; FR, food restricted . 
* Significantly different from nondiabetic group (within group). 
y Significantly different from the nondiabetic WXY. 
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TABLE 3. Systolic arterial pressure (SAP) of nondiabetic and diabetic RVH and 
WKY rats. 
Group 
Nondiabetic 
Diabetic 
Diabetic + T3 
Diabetic + I 
Nondiabetic + T3 
Nondiabetic FR 
Nondiabetic 
Diabetic 
n 
11 
9 
7 
8 
s 
s 
13 
9 
Week 0 
136 ±. 3 
126 ±. 4 
127 ±. 4 
126 ±. 4 
126 ±. 10 
118 ±. 4 
131 ±. 4 
144 ±. 3 
SAP (mmHgJ 
Week 4 
201 + 6y 
194 ±. 12 
194 t 6 
204 ±. 6 
194 + 9 
191 ±. 6 
133 ±. 3 
123 ±. 4 
Week 12 
219 ±. lOY 
191 ±. 14 
243 ±. 8 
196 ±. 7 
215 .±. 12 
203 ±. 18 
140 ±. 3 
140 ±. 7 
Values are means±. SE, obtained before renovascular constriction (week 0), 4 
weeks after surgery and just before induction of diabetes (week 4), and 8 weeks 
after initiation of diabetes or treatment (week 12). T3, triiodothyronine; I, 
insulin; FR, food restricted. 
Y Significantly different from the nondiabetic WKY. 
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TABLE 4. Heart rate (HR) or nondiabetic and diabetic RVH and WKY rats. 
Group n Week 0 
HR (beats/min) 
Week 4 Week 12 
Nondiabetic 11 312 .! 13 381 .! 20 364 .! 15l 
Diabetic 
Diabetic + Tl 
Diabetic + I 
Nondiabetic + Tl 
Nondiabetic FR 
Nondiabetic 
Diabetic 
9 
7 
8 
5 
5 
13 
9 
339 .! 16 
295 .! 5 
313 .t 8 
297 .! 6 
302 .! 5 
l30 .t 19 
285 .t 8 
382 .! 22 
366 .! 26 
364 .t 22 
358 .! 20 
386 .! 25 
316 .t 7 
311 .t 7 
310 .! 14 
386 .! 20 
325 .t 19 
324 .! 8 
310 .! 34 
304 .t 9 
282 ±. 7 
• 
• 
Values are means ±.SB, obtained before renovascular constriction (week 0), 4 
weeks after surgery and just before induction of diabetes (week 4), and 8 weeks 
after initiation of diabetes or treatment (week 12). T3, triiodothyronine; I, 
insulin; FR, food restricted. 
•Significantly different from nondiabetic group (within group). 
l Significantly different from the nondiabetic WKY. 
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Table 5. LVPP stroke work, left ventricular contractility (LV+dP/dt) and 
relaxation (LV-dP/dt) of nondiabetic and diabetic RVH and WXY hearts. 
Group 
Nondiabetic 
Diabetic 
Diabetic + T3 
Diabetic + I 
Nondiabetic + T3 
Nondiabetic FR 
Nondiabetic 
Diabetic 
n 
11 
9 
7 
8 
5 
5 
LVPP 
(kPa) 
22.38 ±. 1.91 
17.72 ± 2.29 1 
21.51 ± 3.34 
24.86 ±. 2.13 
24.76 .± 2.38 
23.23 ±. 1.87 
Stroke Work 
(mJ/g) 
2.44 ±. 0.34 
1.90 ± 0.43 
2.23 ± 0.72 
2.33 ±. 0.54 
2.32 .± 0.53 
2.25 ±. 0.37 
LV+dP/dt 
(kPa/sec) 
991 ±. 139 
t 
651 ± 110 
tt 
810 ±. 154 
914 ±. 81 
1029 .± 130 
902 ±. 72 
13 20.40 ±. 2.74 2.30 ±. 0.59 884 ±. 114 
9 17.93 ±. 1.88 2.25 ±. 0.69 638 ±. 90 
LV-dP/dt 
(kPa/sec) 
666 ±. 108 
529 + 99 
645 ±. 112 
726 ±. 128 
741 ±. 96 
689 ±. 108 
582 ±. 130 
547 ±. 115 
Values are means ±. SO, obtained 8 weeks after initiation of treatment or 
t 
diabetes. Left atrial filling pressure was fixed at 20 cm H2o and resistance 
to aortic ejection was fixed at 1.54 kPa/cm3/min. Same values are also 
represented in Figures 1 and 3. LVPP, left ventricular pulse pressure; T3, 
triiodothyronine; I, insulin; FR, food restricted. 
t Significantly different from nondiabetic group (within group). 
tt Significantly different from nondiabetic and diabetic groups (within group). 
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TABLE 6. Myocardial oxygen consumption cvo2J, cardiac output (CO), power and 
efficiency of contraction (El of nondiabetic and diabetic RVH and 
WKY. 
Group 
Nondiabetic 
Diabetic 
Diabetic + r 3 
Diabetic + I 
Nondiabetic + T3 
Nondiabetic FR 
Nondiabetic 
Diabetic 
11 
9 
7 
8 
5 
5 
13 
9 
f O 
(c11 /sec/g) 
5.06 ±. 1. 04 0.48 ±. 0.07 
4.09 ±. 1. 34 0.46 ±. 0.09 
5.30 ±. 1. 31 0.47 ±. 0 .10 
4.83 ±. 1.38 0.42 ±. 0.08 
5.00 !. 0.85 0.40 i 0.06 
4. 41 ±. 1.09 0.44 ±. 0.07 
9.99 
7.72 
9.93 
Power 
(mW/g) 
±. 2.01 
±. 2.22 
±. 3.11 
9.78 ±. 2.62 
8.85 !. 2.15 
9.87 ±. 1.64 
2.00 ±. 0.31 
1.92 ±. 0. 54 
1.84 !,0.24 
2.06 ±. 0.33 
1. 76 !. 0.26 
2.30 ±. 0.47 
4.98 ±. 0.94 0.48 ±. 0.07 9.19 ±. 2.04 1.86 ±. 0.36 
4.96 ±. 1.02 0.56 ±. 0.14 9.71 i 3.45 1.97 ±. 0.57 
Values are means ±. SD, obtained 8 weeks after initiation of treatment or 
diabetes. Left atrial filling pressure was fixed at 15 cm H2o and resistance 
to aortic ejection was fixed at 1.54 kPa/cm3/min. T3, triiodothyronine; I, 
insulin; FR, food restricted. 
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TABLE 7. Coronary flow rate (CFR) and coronary vascular resistance (CVR) of 
nondiabetic and and diabetic RVH and WKY. 
Group 
Nondiabetic 
Diabetic 
Diabetic t T3 
Diabetic t I 
Nondiabetic t T3 
Nondlabetic FR 
Nondiabetic 
Diabetic 
n 
11 
9 
7 
8 
5 
5 
13 
9 
J CFR J (cm /sec) (cm /sec/g) 
0.45 .± 0.13 0.29 .± 0.07 
t 0.31 ±. 0 .10 0.26 ±. 0.08 
0.37 !,0.11 0.30 ±. 0.08 
0.40 ±. 0.12 0.27 ±. 0.08 
0.42 .± 0.10 0.26 ±. 0.05 
t 0.28 ±. 0.09 0.24 ±. 0.08 
0.44 ±. 0.08 0.31 ±. 0.05 
0.40 ±. 0.10 0.38 ±. 0.11 
c~ (kPa/cm /sec/g) 
70.55 .± 5.461 
62.92 ±. 4. 67 
65.64 ±. 8.83 
72.64 ±. 3.68 
79.19 .± 5.56 
97.02 ±. 7 .31* 
59.70 ±. 4.32 
45.05 ±. 2.65* 
CFR values are means ±. SD and CVR values are means ±. SE, obtained 8 veeks after 
initiation of diabetes or treatment. CFR was measured when left atrial filling 
pressure was fixed at 15 cm H2o and resistance to aortic ejection was fixed at 
1.54 kPa/cm3/min. CVR (normalized for wet heart weight), when hearts were 
pressure loaded. T3, trliodothyronine; I, insulin; FR, food restricted. 
*Significantly different from nondiabetic group (within group). 
1Significantly different from the nondiabetlc WKY. 
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FIGURE 1. Cardiac performance ex vivo as measured by left 
ventricular pulse pressure (LVPP) of nondiabetic (0), diabetic (I), 
T3-treated diabetic (•) and insulin-treated diabetic (•), T3 treated 
nondiabetic (A) RVH. The hearts were pressure loaded by varying the 
resistance to aortic ejection between 0.19 and 3.13 kPa/cm3.min-1 . 
Left atrial filling pressure was fixed at 15 cm H2o. The number of 
animals in each group is shown in parenthesis. Values are means + 
SD, obtained 8 weeks after initiation of diabetes or treatment. 
* Significantly different from the nondiabetic group. 
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FIGURE 2. Left ventricular pressure (LVP) waves from perfused 
working hearts of nondiabetic, diabetic, insulin-treated diabetic and 
T3-treated diabetic RVH, under increasing pressure-loading 
conditions. Each of the four superimposed LVP waves .was obtained at 
one of four resistances to aortic ejection: 0.19, 0.41, 1.54 and 
3 -1 3.13 kPa/cm .min . Left atrial filling pressure was fixed at 15 cm 
H2o. LVP waves were recorded from a single heart in each group and 
were obtained eight weeks after initiation of diabetes or treatment. 
Analog signals were digitized and stored on a diskette and 
regenerated using an IBM PC II with ASYST software and an HP7470 
plotter. Individual records were selected with the aim of 
approximating, as closely as possible, the mean maximum LVP values 
for each group as shown in Figure 1. 
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APPENDIX B: Data Acquisition Programs 
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\ TRIG. GER 
\ The following program allows data acquisition to be 
\ sampled from channel #1 when the external trigger 
\ button on the Narcotrace recorder is pressed. 
DT2800 
INTEGER SCALAR T.RATE 
20 T.RATE .-
INTEGER DIM[ 250 l ARRAY DATA.BUF.l INTEGER DIM[ 250 l ARRAY 
DATA.BUF.2 
1 1 AID.TEMPLATE CHNL.l.IN 
DATA.BUF.l DATA.BUF.2 CYCLIC DOUBLE.TEMPLATE.BUFFERS 
START.ACQ 
CHNL.l.IN AID.INIT 
3 AID.GAIN A/D.INIT 
CLEAR.TASKS 
1 TASK A/D.IN>ARRAY 
T.RATE TASK.PERIOD 
PRIME.TASKS 
TRIGGER . TASKS ; 
STOP.ACQ 
STOP.TASKS 
CLEAR.TASKS ; 
PLOT. IT 
BEGIN 
ERASE . LINES 
BEGIN ?BUFFER.SWITCH 
?BUFFER.AIB 
\ Starts data acquisition, 
\ input on channel 1 
\ Stops data acquisition 
\ 
\ 
\ 
UNTIL 
Plots data continually until 
a key is pressed. This is 
used for checking calibration 
\ of machines 
IF DATA.BUF.l ELSE DATA.BUF.2 
THEN 2 217 AID.SCALE Y.DATA.PLOT 
?KEY UNTIL ; 
. REAL DIM[ 5000 ARRAY PIXBUF 
SET.GRAPHICS 
GRAPHICS.DISPLAY 
AXIS.FIT.OFF 
\ Sets graphics display for 
\ checking calibration 
HORIZONTAL O. 250. WORLD.SET 
VERTICAL 0. 150. WORLD.SET 
OUTLINE 
XY.AXIS.PLOT 
PIXBUF LINE.BUFFER.ON 
\ Sets graphics display for 
\ acquired data points 
SET.GRAPHS 
GRAPHICS.DISPLAY 
AXIS.FIT.OFF 
HORIZONTAL 0. 1000. WORLD.SET 
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AXIS.FIT.OFF 
VERTICAL 0. 250. WORLD.SET 
OUTLINE 
XY.AXIS.PLOT \ Show axis and grid lines 
PIXBUF LINE.BUFFER.ON 
CHECK. IT 
SET.GRAPHICS 
START.ACQ 
PLOT. IT 
STOP.ACQ ; 
\ Allows continual monitoring 
\ of input for checking 
\ calibration 
\DOES NOT STORE DATA!!!!! 
1 1 aid . template 5PP EXT.TRIG AID.INIT 
integer dim[ 1000 1 array BEAT 
BEAT template.buffer A/D.INIT \ Defines the input channel tl 
2. conversion.delay ald.init \ to be activated by an external 
INTEGER SCALAR COUNT \ trigger signal. Sets array size 0 
COUNT .- \ (how many data points to be 
\ collected and stored) 
YUP 5PP EXT.TRIG AID.INIT 
3 AID.GAIN A/D.INIT \ Waits for external trigger to 
STACK.CLEAR \ be pressed before acquiring data 
BEG.IN BELL AID.IN>ARRAY \ BELL rings before data is 
?BUFFER.FULL \ collected then another BELL after 
UNTIL BELL \ data collection is complete 
COUNT SUBFILE BEAT ARRAY>FILE 
COUNT . , 
GRAPHS 
BEAT 2 217 AID.SCALE 
Y. DATA . PLOT ; 
14 STRING FILENAME 
CREATE.DATA.FILE 
FILE.TEMPLATE 
15 COMMENTS 
BEAT []FORM.SUBFILE 
15 TIMES 
END 
\ Graphs acquired data 
\ Creates a file on a disk (be 
\ sure to specify B:FILENAME) 
\ 15 subfiles are available, 
\ therefore, 15 separate arrays 
\ can be acquired and stored 
CR ." NAME OF FILE TO CREATE? " 
"INPUT FILENAME ":= 
FILENAME DEFER> FILE.CREATE 
FILE.OPEN ; 
RESTART. IT 
BEGIN 
COUNT 1 + COUNT := 
YUP 
ERASE.LINES 
GRAPHS 
?KEY UNTIL ; 
\ Adds sequential numbers to number 
\ stack so that subsequent data 
\ points (arrays) are put in 
\ consecutive subfiles 
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CLEAN.UP 
LINE.BUFFER.OFF 
AXIS. DEFAULTS 
SCREEN.CLEAR 
CR ." Data acquisition finished" 
CR 
BELL ; 
END.DATA.ACQ 
FILE.CLOSE 
0 COUNT := 
CLEAN.UP ; 
F9 FUNCTION.KEY.DOES END.DATA.ACQ 
GO.TEAM 
CREATE.DATA.FILE 
SET.GRAPHS 
RESTART.IT ; 
\ Initiates program to create 
\ a data file and collect data 
\ To check machine calibration, type "CHECK.IT (return)". 
\To initiate the program to store data, type "GO.TEAM (return)". 
\ To end data acquisition and close data file, press 
\ F9 and HIT the external trigger one more time. 
\ "OH BOY!" 
BELL BELL 
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\ EXT.TRG 
\ This program allows user to monitor and store 
\ electrophysiological data from channel #2 
\ (e.g., cardiac action potentials) 
\ Data acquisition is controlled by an external trigger signal 
\ or continually monitored for calibration 
DT2800 
INSTRUCTIONS 
CR " <F3> 
CR " <F5> 
CR II <F7> 
CR " <F9> 
End data acquisition 
Create a data file 
Change sensitivity 
View potentials 
REAL SCALAR DEFAULT.NUMBER 
SENSITIVITY 
<F4> 
<FG> 
<F8> 
<FlO> 
Continual display " 
Instructions " 
Set graphics " 
Add to data file " 
CR ." Select sensitivity, 
.125 DEFAULT.NUMBER := 
#INPUT 
e.g., .2 or .5 (else .125) " 
IF 
DEFAULT.NUMBER .-
THEN 
INSTRUCTIONS ; 
\ Asks user for the desired 
\ sensitivity, default value 
\ was good for AJD (8/89) 
REAL DIM( 5000 ARRAY PIXBUF 
SET.GRAPHICS 
VUPORT.CLEAR 
0. 200. HORIZONTAL 
-.125 .025 VERTICAL 
XY.AXIS.PLOT 
PIXBUF LINE.BUFFER.ON 
\ Set axes to 
\ data points 
WORLD.SET 
WORLD.SET 
plot acquired 
(arrays) 
2 2 A/D.TEMPLATE CHNL2 EXT.TRIG 
INTEGER DIM[ 200 l ARRAY APS 
APS TEMPLATE.BUFFER 
\ Define input channel #2 
\ controlled by external 
\ trigger signal 
INTEGER SCALAR COUNT 
0 COUNT := 
14 STRING FILENAME 
CREATE.DATA.FILE 
FILE.TEMPLATE 
APS []FORM.SUBFILE 
30 TIMES 
END 
\ Create a data file to store 
\ acquired data points 
\ Prompts user for file name 
\ BE SURE to specify B:FILENAME! 
\ Allows 30 ARRAYS to be collected 
CR . " Name of file to create? " 
"INPUT FILENAME ":= 
FILENAME DEFER> FILE.CREATE 
FILE.OPEN ; 
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CLEAN.UP 
LINE.BUFFER.OFF 
AXIS.DEFAULTS 
SCREEN.CLEAR 
VUPORT.CLEAR 
\ Resets default values 
CR ." Data acquisition finished, YEAH!? " 
CR 
BELL ; 
END.DATA.ACQ 
FILE.CLOSE 
0 COUNT := 
CLEAN.UP ; 
START. AGAIN 
CHNL2 
3 AID.GAIN AID.INIT 
BEGIN 
AID.IN>ARRAY 
?BUFFER.FULL 
UNTIL BELL ; 
GRAPH. IT 
APS DEFAULT.NUMBER -1 * 
DEFAULT.NUMBER AID.SCALE 
Y.DATA.PLOT; 
\ Ends data acquisition, 
\ closes file and resP.ts 
\ count to equal 0 
\ Initiates data collection 
\ BELL rings when complete 
\ DOES NOT STORE DATA! 
\ Scales and plots acquired data 
ADD.TO.DATAFILE \ Collects, STORES and graphs data 
COUNT 1 t COUNT .-
START.AGAIN 
COUNT SUBFILE APS ARRAY>FILE BELL 
COUNT 
GRAPH.IT ; 
VIEW. IT 
START .AGAIN 
GRAPH. IT ; 
GET. IT 
SUBFILE APS FILE>ARRAY 
APS DEFAULT.NUMBER -1 * 
DEFAULT.NUMBER AID.SCALE 
Y.DATA.PLOT ; 
INTEGER DIM( 200 l ARRAY APS.l 
2 2 AID.TEMPLATE CHNLl 
CYCLIC TEMPLATE.BUFFER 
INTEGER SCALAR T.RATE 
2. T.RATE .-
SET.UP 
CHNLl 
\ Collects data (without storing) 
\ and graphs it 
\ Used to check stored data 
\ Put number on number stack 
\ (type a number and return) 
\ then GET. IT 
\ Defines channel t2 as cyclical APS.l 
\ in order to continually plot 
\ BUT NOT STORE data 
\ Use to check calibration 
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3 AID.GAIN AID.INIT 
CLEAR.TASKS 
1 TASK AID.IN>ARRAY 
T.RATE TASK.PERIOD 
PRIME.TASKS 
TRIGGER.TASKS 
START.ACQ \ Starts data acquisition 
BEGIN \ continually plots input 
ERASE.LINES \ data until a key is pressed 
BEGIN ?BUFFER.SWITCH UNTIL 
APS.l DEFAULT.NUMBER -1 * 
DEFAULT.NUMBER AID.SCALE 
Y.DATA.PLOT 
?KEY UNTIL BELL ; 
STOP.ACQ 
STOP.TASKS 
CLEAR.TASKS 
CONTINUOUS 
SET.UP 
START.ACQ 
STOP.ACQ 
CLEAR. TASKS 
20 0 24 79 WINDOW {BOT} 
GO.TEAM 
CREATE.DATA.FILE 
SENSITIVITY 
DEFAULT.NUMBER 
GRAPHICS.DISPLAY 
SCREEN.CLEAR 
{BOT} 
0 .20 VUPORT.ORIG 
1 .80 VUPORT.SIZE 
INSTRUCTIONS ; 
\ Stops data acquisition 
\ Initiates program to continually 
\ monitor input, WITHOUT storing 
\ the data 
\ Defines vuport space for 
\ instructions 
\ Initiates program to create a 
\ data file, set sensitivity, set 
\ graphics display, present 
\ instructions 
\ Save bottom four lines 
\ for text 
F3 FUNCTION.KEY.DOES END.DATA.ACQ 
F4 FUNCTION.KEY.DOES CONTINUOUS 
F5 FUNCTION.KEY.DOES CREATE.DATA.FILE 
F6 FUNCTION.KEY.DOES INSTRUCTIONS 
F7 FUNCTION.KEY.DOES SENSITIVITY 
F8 FUNCTION.KEY.DOES SET.GRAPHICS 
F9 FUNCTION.KEY.DOES VIEW.IT 
FlO FUNCTION.KEY.DOES ADD.TO.DATAFILE 
BELL BELL 
\To initiate program, type "GO.TEAM (return)". 
\ If you are not sure what to do, type "INSTRUCTIONS (return)" 
\ at any time to refresh instruction screen 
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\ If you ever want to overwrite collected data, type "t COUNT := 
\ (return)". Specify the number (#) corresponding to the subfile 
\ PRIOR TO the one you want to write over (e.g., 3 COUNT := will 
\ set count to 3, when EXT TRIG is pressed, data will be stored 
\ in subfile #4 
\ To end data acquisition and close file press (F3) 
\ Program allows for 30 arrays to be stored 
\ GOOD LUCK MR/MS PHELPS! 
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\ ANALYZE.LVP 
\ Program allows user to look at stored data points (arrays) 
\ within a file, plot the arrays, extract a portion (300 msec), 
\ plot subset on HP plotter, and store that subset in a 
\ SEPARATE file 
DT2800 
LOOK.SEE 
GRAPHICS.DISPLAY 
AXIS.DEFAULTS 
HORIZONTAL 0 1000 WORLD.SET 
VERTICAL 0 180 WORLD.SET 
GRAPHICS.READOUT 
NORMAL.COORDS 
.7 .975 READOUT>POSITION 
XY.AXIS.PLOT ; 
SUBPLOT.AXES 
VUPORT.CLEAR 
HORIZONTAL 0 270 WORLD.SET 
VERTICAL 0 180 WORLD.SET 
XY.AXIS.PLOT 
LABEL.PLOT 
NORMAL.COORDS 
.5 .05 POSITION 
" TIME (msec) 11 LABEL 
90 LABEL.DIR 
.025 .4 POSITION 
II L VP ( mmHg) II LABEL 
WORLD.COORDS ; 
45 STRING ANIMAL 
HEADER 
NORHAL.COORDS 
0 LABEL.DIR 
. 4 . 9 5 POSITION 
\ Sets up axes to view stored 
\ LVPs (arrays) in data file 
\ Sets up axes to view subsets 
\ of LVPs in data file 
\ Defines coordinates, axes and 
\ labels axes on HP plotter 
\ Asks for title name for the 
\ graph to be plotted 
CR . 11 Animal number and group? 
"INPUT ANIMAL 11 := 
II 
ANIMAL LABEL i 
HP.PLOTTER 
HP7470 
PLOTTER.DEFAULTS 
SUBPLOT.AXES 
LABEL.PLOT 
HEADER 
PLOT. IT 
Y.DATA.PLOT 
STACK.CLEAR i 
\ Plots axes, labels and title 
\ Plot a named array (LVP) either 
\ on CRT screen or on HP plotter 
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INTEGER DIM( 1000 l ARRAY LVP 
GET. IT 
SUBFILE LVP FILE>ARRAY 
LVP 0 200 AID.SCALE 
SCALAR RANGES 
RESCALE.IT 
." Range for scaling? " 
#INPUT RANGES := 
SUBFILE LVP FILE>ARRAY 
LVP 0 RANGES AID.SCALE ; 
\ Waits for a number on number 
\ stack (e.g., 1 for subfile 1 
\ which contains FPlS), reads 
\ the array and plots it 
\ Allows user to rescale raw 
\ data stored in files, if 
\ calibration was incorrect 
INTEGER DIM( 300 ARRAY FPlS 
INTEGER DIM! 300 ARRAY FP20 
INTEGER DIM( 300 ARRAY FPlO 
INTEGER DIM( 300 ARRAY FPS 
INTEGER DIM( 300 ARRAY RJ 
INTEGER DIM[ 300 ARRAY R4 
INTEGER DIM( 300 ARRAY R2 
INTEGER DIM[ 300 ARRAY Rl 
SCALAR STARTING.PT 
DEFINE. IT 
CR ." Starting point? " 
#INPUT STARTING.PT := 
SUB[ STARTING.PT , 300 
CR " Array Name? " 
14 STRING FILENAME 
INTEGER DIM[ 300 l ARRAY LVPP 
CREATE.SUB.FILE 
FILE.TEMPLATE 
8 COMMENTS 
LVPP []FORM.SUBFILE 
8 TIMES 
\ Defines subset of arrays in 
\data file (for area analysis) 
\ specify starting point (X-axis) 
\ Name the subset (e.g., FPlS or 
\ R3) 
\ Create a file to store the 
\ defined subsets 
END CR ."Name of file to create? " 
"INPUT FILENAME ":= 
FILENAME DEFER> FILE.CREATE FILE.OPEN 
II FPlS" 1 >COMMENT 
" FP20" 2 >COMMENT 
II FPlO" 3 >COMMENT 
" FPS" 4 >COMMENT 
II R3" s >COMMENT 
II R4" 6 >COMMENT 
II R2" 7 >COMMENT 
" Rl" 8 >COMMENT 
BELL ; 
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WRITE. IT 
1 SUBFILE FP15 
2 SUBFILE FP20 
3 SUBFILE FPlO 
4 SUBFILE FPS 
5 SUBFILE R3 
ARRAY> FILE 
ARRAY> FILE 
ARRAY>FILE 
ARRAY> FILE 
ARRAY> FILE 
ARRAY> FILE 
ARRAY>FILE 
ARRAY> FILE 
\ Stores defined subsets into 
\ newly created file 
6 SUBFILE R4 
7 SUBFILE R2 
8 SUBFILE Rl 
BELL ; 
F2 FUNCTION.KEY.DOES RESCALE.IT 
F3 FUNCTION.KEY.DOES PLOT.IT 
F4 FUNCTION.KEY.DOES CREATE.SUB.FILE 
F5 FUNCTION.KEY.DOES SUBPLOT.AXES 
F6 FUNCTION.KEY.DOES LOOK.SEE 
F7 FUNCTION.KEY.DOES GET.IT 
F8 FUNCTION.KEY.DOES DEFINE.IT 
F9 FUNCTION.KEY.DOES HP.PLOTTER 
FlO FUNCTION.KEY.DOES WRITE.IT 
BELL BELL 
\ To initiate program, open data file in drive B: 
\ (FILE.OPEN B:filename). 
\ Plot LOOK.SEE axes (F6), type a number corresponding to desired 
\ subfile, and plot it or GET.IT (F7). 
\ Cursor can be used to determine starting point for subset 
\ (position cursor and press HOME KEY for read out - see ASYST 
\ manual for more detail on cursor movement). 
\ Before creating a new file for the subset arrays, be sure to 
\ close the parent file (FILE.CLOSE), then CREATE.SUB.FILE 
\ (F4). 
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\ AREA.PLT 
\ Program allows user to call up (GET.IT) stored subfiles, 
\ graph the arrays, and move cursor around to outline LVP wave 
\ (e.g., from Pmax to max EDP), in order to calculate the 
\ area defined 
DT2800 
COMPLEX SCALAR ZO REAL 
SCALAR AREA AXIS.DEFAULTS 
NEXT. POINT 
SWAP CONJ 
OVER * 
ZIHAG 
2. I 
AREA + AREA := 
POINT 
?CURSOR 
3 PICK 
ZRE&IH POSITION 
DRAW.TO 
?CURSOR 
Z=X+IY 
NEXT .POINT 
FIRST. POINT 
?CURSOR 
Z=X+IY 
DUP ZO := 
0. AREA := 
BELL ; 
LAST.POINT 
POINT 
ZO ZRE&IH DRAW.TO 
ZO NEXT.POINT DROP 
GRAPHICS.READOUT 
CR AREA . 
BELL 
STACK.CLEAR 
SUBPLOT.AXES 
GRAPHICS.DISPLAY 
HORIZONTAL 0 270 WORLD.SET 
VERTICAL 0 180 WORLD.SET 
GRAPHICS.READOUT 
NORHAL.COORDS 
.7 .975 READOUT>POSITION 
WORLD.COORDS 
XY.AXIS.PLOT 
PLOT. IT 
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Y.DATA.PLOT 
ARRAY.READOUT 
INTEGER DIM( 300 ARRAY WAVES 
GET.IT 
SUBFILE WAVES FILE>ARRAY 
WAVES 
PLOT.IT 
\ Reads the subfile specified by 
\ the number placed on number stack 
Fl FUNCTION.KEY.DOES FIRST.POINT 
F2 FUNCTION.KEY.DOES POINT 
F3 FUNCTION.KEY.DOES LAST.POINT 
FS FUNCTION.KEY.DOES SUBPLOT.AXES 
F7 FUNCTION.KEY.DOES GET.IT 
F8 FUNCTION.KEY.DOES PLOT.IT 
BELL BELL 
\ NOTE: See ASYST manual for more detailed instruction about 
\ 
\ 
\ 
\ 
\ 
\ 
cursor movement. 
ARROWS on key pad moves cursor. 
HOME KEY gives read out of present cursor position. 
PG UP changes the increment of cursor movement, e.g., strike 
once = slowest or smallest distance moved, strike multiple 
times in succession = larger increments. 
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\ ANALYZE.APS 
\ This program allows user to analyze the area of AP records, 
\ AP durations, RMPs, dV/dt's, and plot APs -0n HP plotter 
\ Type the word "INSTRUCTIONS" to list function key assignments 
DT2800 
COMPLEX SCALAR ZO REAL SCALAR AREA 
NEXT. POINT 
SWAP CONJ 
OVER * 
ZIMAG 
2. I 
AREA + AREA .-
POINT 
?CURSOR 
3 PICK 
ZRE&IM POSITION 
DRAW. TO 
?CURSOR 
Z=X+IY 
NEXT.POINT 
FIRST.POINT 
?CURSOR 
Z=x+ I Y 
DUP ZO 
0. AREA 
BELL ; 
LAST.POINT 
POINT 
. -
.-
ZO ZRE&IM DRAW.TO 
ZO NEXT.POINT DROP 
GRAPHICS.READOUT 
CR AREA . 
BELL 
STACK.CLEAR ; 
GRAPHS 
VUPORT.CLEAR 
AXIS.DEFAULTS 
HORIZONTAL 0 200 WORLD.SET 
VERTICAL -125 25 WORLD.SET 
GRAPHICS.READOUT 
NORMAL.COORDS 
.7 .975 READOUT>POSITION 
XY.AXIS.PLOT ; 
LABEL.PLOT 
NORMAL.COORDS 
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.5 .05 POSITION 
" TIME (msec)" LABEL 
90 LABEL. DIR 
.025 .4 POSITION 
" MP ( mV)" LABEL 
WORLD.COORDS ; 
45 STRING ANIMAL 
HEADER 
NORMAL.COORDS 
0 LABEL.DIR 
.4 .95 POSITION 
CR . " Animal number and group? 
"INPUT ANIMAL ":= 
ANIMAL LABEL 
WORLD.COORDS 
HP.PLOTTER 
HP7470 
PLOTTER.DEFAULTS 
VUPORT.CLEAR 
HORIZONTAL 0 200 WORLD.SET 
VERTICAL -125 25 WORLD.SET 
XY.AXIS.PLOT 
LABEL.PLOT 
HEADER ; 
" 
INTEGER DIM[ 200 I ARRAY APS INTEGER DIM[ 200 l ARRAY AP 
GET. IT 
0 AP := 
SUBFILE APS FILE>ARRAY 
APS -125 125 AID.SCALE 
AP : = ; 
.5 SET.CUTOFF.FREQ 1 SET.#.OPTIMA 
VMAX 
DIFFERENTIATE.DATA 
INTEGER DIM[ 200 
INTEGER DIM[ 200 
INTEGER DIM[ 200 
INTEGER DIM[ 200 
INTEGER DIM[ 200 
INTEGER DIM[ 200 
INTEGER DIM[ 200 
INTEGER DIM[ 200 
INTEGER DIM[ 200 
INTEGER DIM[ 200 
INTEGER DIM[ 200 
INTEGER DIM[ 200 
ARRAY APl 
ARRAY AP2 
ARRAY AP3 
ARRAY AP4 
ARRAY AP5 
ARRAY AP6 
ARRAY AP? 
ARRAY AP8 
ARRAY AP9 
ARRAY APlO 
ARRAY APll 
ARRAY AP12 
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INTEGER DIM( 200 
INTEGER DIM( 200 
INTEGER DIM( 200 
INTEGER DIM( 200 
INTEGER DIM( 200 
INTEGER DIM( 200 
INTEGER DIM( 200 
INTEGER DIM( 200 
INTEGER DIM( 200 
INTEGER DIM( 200 
INTEGER DIM( 200 
INTEGER DIM( 200 
INTEGER DIM( 200 
INTEGER DIM( 200 
INTEGER DIM( 200 
INTEGER DIM( 200 
INTEGER DIM( 200 
INTEGER DIM( 200 
GET.THEM 
ARRAY AP13 
ARRAY AP14 
ARRAY AP15 
ARRAY AP16 
ARRAY APl 7 
ARRAY AP18 
ARRAY AP19 
ARRAY AP20 
ARRAY AP21 
ARRAY AP22 
ARRAY AP23 
ARRAY AP24 
ARRAY AP25 
ARRAY AP26 
ARRAY AP27 
ARRAY AP28 
ARRAY AP29 
ARRAY APJO 
1 SUBFILE APl FILE>ARRAY 
APl -125 125 AID.SCALE APl .-
2 SUBFILE AP2 FILE>ARRAY 
AP2 -125 125 AID.SCALE AP2 .-
3 SUBFILE AP3 FILE>ARRAY 
AP3 -125 125 AID.SCALE APJ .-
4 SUBFILE AP4 FILE>ARRAY 
AP4 -125 125 AID.SCALE AP4 .-
5 SUBFILE AP5 FILE>ARRAY 
AP5 -125 125 AID.SCALE AP5 .-
6 SUBFILE AP6 FILE>ARRAY 
AP6 -125 125 AID.SCALE AP6 .-
7 SUBFILE AP7 FILE>ARRAY 
AP7 -125 125 AID.SCALE AP7 .-
8 SUBFILE AP8 FILE>ARRAY 
AP8 -125 125 AID.SCALE AP8 .-
9 SUBFILE AP9 FILE>ARRAY 
AP9 -125 125 AID.SCALE AP9 .-
10 SUBFILE APlO FILE>ARRAY 
APlO -125 125 AID.SCALE APlO .-
11 SUBFILE APll FILE>ARRAY 
APll -125 125 AID.SCALE APll .-
12 SUBFILE AP12 FILE>ARRAY 
AP12 -125 125 AID.SCALE AP12 .-
13 SUBFILE AP13 FILE>ARRAY 
AP13 -125 125 AID.SCALE AP13 .-
14 SUBFILE AP14 FILE>ARRAY 
AP14 -125 125 AID.SCALE AP14 .-
15 SUBFILE AP15 FILE>ARRAY 
AP15 -125 125 AID.SCALE AP15 .-
16 SUBFILE AP16 FILE>ARRAY 
AP16 -125 125 AID.SCALE AP16 .-
17 SUBFILE AP17 FILE>ARRAY 
AP17 -125 125 AID.SCALE AP17 .-
-168-
18 SUBFILE AP18 FILE>ARRAY 
AP18 -125 125 AID.SCALE AP18 . -
19 SUBFILE AP19 FILE>ARRAY 
AP19 -125 125 AID.SCALE AP19 .-
20 SUBFILE AP20 FILE>ARRAY 
AP20 -125 125 AID.SCALE AP20 . -
21 SUBFILE AP21 FILE>ARRAY 
AP21 -125 125 AID.SCALE AP21 .-
22 SUBFILE AP22 FILE>ARRAY 
AP22 -125 125 AID.SCALE AP22 . -
23 SUBFILE AP23 FILE>ARRAY 
AP23 -125 125 AID.SCALE AP23 : = 
24 SUBFILE AP24 FILE>ARRAY 
AP24 -125 125 AID.SCALE AP24 . -
25 SUBFILE AP25 FILE>ARRAY 
AP25 -125 125 AID.SCALE AP25 .-
26 SUBFILE AP26 FILE>ARRAY 
AP26 -125 125 AID.SCALE AP26 . -
27 SUBFILE AP27 FILE>ARRAY 
AP27 -125 125 AID.SCALE AP27 . -
28 SUBFILE AP28 FILE>ARRAY 
AP28 -125 125 AID.SCALE AP28 . -
29 SUBFILE AP29 FILE>ARRAY 
AP29 -125 125 AID.SCALE AP29 
30 SUBFILE AP30 FILE>ARRAY 
AP30 -125 125 AID.SCALE AP30 . -
BELL ; 
INSTRUCTIONS 
CR II 
CR II <F5> Get one array from file 
CR II <F7> Plotter 
CR II <F9> Get all arrays from file 
PLOT. IT 
Y.DATA.PLOT 
STACK.CLEAR 
LOCATE. IT 
LOCAL.MAXIMA 
POSITION ; 
20 0 24 79 WINDOW {BOT} 
GO.TEAM 
GRAPHICS.DISPLAY 
SCREEN.CLEAR 
{BOT} 
0 .20 VUPORT.ORIG 
1 .80 VUPORT.SIZE 
INSTRUCTIONS ; 
Fl FUNCTION.KEY.DOES FIRST.POINT 
-169-
<F4> Plot array II 
<F6> Vmax for array " 
<F8> Set graphics II 
<FlO> Locate Vmax ff 
F2 FUNCTION.KEY.DOES POINT 
F3 FUNCTION.KEY.DOES LAST.POINT 
F4 FUNCTION.KEY.DOES PLOT.IT 
F5 FUNCTION.KEY.DOES GET.IT 
FG FUNCTION.KEY.DOES VMAX 
F7 FUNCTION.KEY.DOES HP.PLOTTER 
F8 FUNCTION.KEY.DOES GRAPHS 
F9 FUNCTION.KEY.DOES GET.THEM 
FlO FUNCTION.KEY.DOES LOCATE.IT 
\ Type GO.TEAM to initiate program or to return graphics to 
\ the CRT rather than the plotter 
BELL BELL 
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